MERCK
MRKMerck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
Drugs in Pipeline
837
Phase 3 Programs
448
Upcoming Catalysts
50
Next Catalyst
Oct 23, 2026
20dMarket Overview
Stock performance and key metrics
50 upcoming, 5 past
Upcoming FDA decisions
How MRK's past catalysts played out
ULO
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
Measles
100 mg clindamycin /800 mg ketoconazole vaginal ovule
Vaginosis, Bacterial
Telcagepant 140 mg
Migraines
Telcagepant 300 mg soft gel capsules
Migraine
CXA-201
Complicated Urinary Tract Infection
Rotarix™
Pneumococcal Infections
QIV
Pneumonia, Pneumococcal
Acetaminophen/Paracetamol
Migraine Disorders
MK-3415
Clostridium Difficile Infection
Leucovorin/ levoleucovorin
Metastatic Colorectal Cancer
epinastine nasal spray, low concentration, low dose volume
Seasonal Allergic Rhinitis
Letermovir tablet
Cytomegalovirus Infection
peginterferon alfa-2b (PEG2b) (SCH 54031)
Hepatitis C, Chronic
Prulifloxacin
Acute Gastroenteritis in Adult Travelers
Efalizumab
Moderate to Severe Psoriasis
Suvorexant High Dose (HD)
Primary Insomnia
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Valganciclovir
CMV Disease
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Intra-abdominal Infection
Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Lung Cancer
S-1
Gastric Cancer
Glycopyrrolate
Surgical Procedures, Elective
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
Rotavirus
MK0966 / Duration of Treatment: 1 Days
Pain, Postoperative Arthroscopy
MK0524A, /Duration of Treatment : 4 Weeks
Flushing
Alviompan
Bowel Dysfunction
taranabant
Smoking
regorafenib
Colorectal Cancer
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
Measles
Rebif® New Formulation (IFN-beta-1a, RNF)
Multiple Sclerosis, Relapsing-Remitting
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
Cervical Cancer
sitagliptin phosphate (+) metformin hydrochloride
Type 2 Diabetes Mellitus
Peginterferon alfa-2b (PEG)
Hepatitis C, Chronic
Cladribine Low Dose
Generalized Myasthenia Gravis
Rocuronium bromide (Zemuron)
Anesthesia
Colistimethate sodium (CMS)
Bacterial Infections
Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Cervical Cancer
ART
HIV-1 Infection
Acarbose
Type 2 Diabetes Mellitus
Pegylated interferon alfa-2b (PegIntron)
Hepatitis B, Chronic (CHB)
Sitagliptin plus metformin
Type 2 Diabetes Mellitus
V110, pneumococcal vaccine polyvalent
Healthy
Linezolid
Pneumonia
Zanzalintinib
Renal Cell Carcinoma
liposomal doxorubicin
Breast Neoplasms
diquafosol tetrasodium (INS365) ophthalmic solution
Dry Eye Disease
Sofosbuvir
Hepatitis C
Intismeran
Non-small Cell Lung Cancer
Fluorouracil (5-FU)
Urinary Bladder Neoplasms
AzaSite
Bacterial Conjunctivitis
rosiglitazone
Type 2 Diabetes Mellitus
Elbasvir/Grazoprevir Fixed Dose Combination
Chronic HCV Infection
VARIVAX™ New Seed Process
Varicella
Reformulated Raltegravir
HIV Infection
Pneumococcal Vaccine, Polyvalent (23-valent)
Pneumococcal Infection
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
HPV Infections
levoleucovorin
Esophageal Squamous Cell Carcinoma (ESCC)
2XP HEPTAVAX™-II SC
Hepatitis B
V110
Pneumococcal Infection
RotaTeq (V260)
Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9
Cetuximab plus Platinum-based Doublet Chemotherapy
Non-Small Cell Lung Cancer (NSCLC)
Background PAH Therapy
Pulmonary Arterial Hypertension
MK-0524B
Primary Hypercholesterolemia
L-PZQ ODT 50 mg/kg
Schistosomiasis
boceprevir (SCH 503034)
Chronic Hepatitis C
lovastatin
Atherosclerosis
Aprepitant
Post-operative Nausea
DOR
HIV-1 Infection
MMRV (AMP)
Measles
Folinic Acid
Metastatic Colorectal Cancer
Lamivudine
HIV Infections
RotaTeq™ experimental formulation
Rotavirus Gastroenteritis
BIC/FTC/TAF
HIV-1 Infection
Ifinatamab Deruxtecan
Castration-Resistant Prostatic Cancer
denufosol tetrasodium (INS37217) Inhalation Solution
Cystic Fibrosis
Bomedemstat
Thrombocythemia, Essential
Sulfonylurea
Type 2 Diabetes Mellitus
Pembrolizumab (MK-3475)
Merkel Cell Carcinoma
Zidovudine
HIV Infections
MK-0518
HIV Infections
Grazoprevir 100mg / Elbasvir 50 mg FDC
Chronic Hepatitis C Virus
succinylcholine
Neuromuscular Blockade
Kuvan®
Phenylketonuria
Tulisokibart
Hidradenitis Suppurativa
MK-1084
Colon Adenocarcinoma
Pioglitazone hydrochloride
Type 2 Diabetes Mellitus
BCG
Urinary Bladder Neoplasms
Rebif®
Clinically Isolated Syndrome
Zoster Vaccine, Live, (Oka-Merck)
Varicella Virus Infection
peg-IFN
Hepatitis C, Chronic
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Chronic Hepatitis C
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Herpes Zoster
Sitagliptin 100 mg/simvastatin 40 mg FDC
Type 2 Diabetes Mellitus
Prevnar 13®
Streptococcus Pneumoniae Infection
MK0991, caspofungin acetate / Duration of Treatment:
Fungal Infection
Ertugliflozin 10 mg
Type 2 Diabetes Mellitus
daptomycin
Pneumonia, Bacterial
MK0831
HIV Infections
Frespaciguat
Pulmonary Hypertension
Preservative-Free Tafluprost
Open-angle Glaucoma
Palivizumab
RSV Infection
Ertugliflozin 5 mg
Type 2 Diabetes Mellitus
Rotateq™
Rotavirus Infections
Clesrovimab
Respiratory Syncytial Viruses
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)
Measles
alvimopan
Ileus
Filgrastim
Metastatic Non-small Cell Lung Cancer
V503 Vaccine
Papillomavirus Infections
granisetron
Chemotherapy-induced Nausea and Vomiting (CINV)
MK-8527
Human Immunodeficiency Virus (HIV)
PCV15 - Part B
Pneumococcal Disease
luspatercept
B-Thalassemia
Zilovertamab vedotin
B-cell Acute Lymphoblastic Leukemia
Saizen® A
Children Born With Serious Intra-uterine Growth Retardation
Doravirine, Tenofovir, Lamivudine
HIV-1 Infection
Pembrolizumab/Quavonlimab
Colorectal Cancer
MK-5172A
Chronic Hepatitis C
PegIntron (peginterferon alfa-2b; SCH 54031)
Hepatitis
Grazoprevir
Chronic Hepatitis C (CHC)
vinflunine
Urothelial Cancer
PEG-Intron
Hepatitis C
Granulocyte Colony-Stimulating Factor (G-CSF)
DLBCL
MK0217, alendronate sodium / Duration of Treatment: 1 Month
Osteoporosis
Nemtabrutinib
Chronic Lymphocytic Leukemia
Emtricitabine/tenofovir disoproxil (FTC/TDF)
Human Immunodeficiency Virus (HIV)
Zoster Vaccine, Live
Herpes Zoster
Efprezimod alfa
Graft Versus Host Disease
Zoster Vaccine, Live (AMP)
Herpes Zoster
Prevnar 13™
Pneumococcal Infections
Cisplatin/Carboplatin
Carcinoma, Squamous Cell of Head and Neck
Pembrolizumab/Vibostolimab
Lung Neoplasms
Modified Process Hepatitis B Vaccine
Hepatitis B
ProQuad® manufactured with recombinant Human Albumin (rHA)
Measles
Gardasil™
Papillomavirus Infections
Varicella Virus Vaccine Live (Oka-Merck)
Varicella
Fosaprepitant dimeglumine
Chemotherapy-Induced Nausea and Vomiting (CINV)
MK0557
Obesity
V181
Healthy
Aprepitant 125 mg
Chemotherapy Induced Nausea and Vomiting
Human Papillomavirus (HPV) 16 Monovalent
Cervical Cancer
PegIntron
Hepatitis C
Atropine
Anesthesia, General
Glycemic Rescue 1
Diabetes Mellitus
Zoster Vaccine, Live (Zostavax™)
Shingles
DOR/ISL
HIV Infection
Rocuronium bromide (Org 9426)
Muscle Relaxation
Axitinib
Renal Cell Carcinoma
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
Type 2 Diabetes Mellitus
Pembrolizumab Formulated with Berahyaluronidase Alfa
Metastatic Non-small Cell Lung Cancer
Rocuronium 0.6 mg/kg intubating dose
Anesthesia
Androgen Deprivation Therapy (ADT)
Metastatic Hormone-Sensitive Prostate Cancer
Pneumovax™ 23
Pneumococcal Infections
Glimerpiride
Type 2 Diabetes Mellitus
caspofungin acetate
Fungal Infection
Posaconazole
Mycoses
Metformin - Rescue
Diabetes Mellitus, Type 2
Infanrix® hexa
Varicella
Cisplatin (as radiosensitizer)
Endometrial Neoplasms
Rocuronium bolus maintenance
Anesthesia
Vecuronium
Anesthesia, General
IV Tulisokibart
Crohn's Disease
Peginterferon alfa-2b (PEG2b)
Hepatitis C, Chronic
V114
Pneumococcal Infections
Peg-interferon alfa-2b
Hepatitis C, Chronic
Daptomycin 4 mg/kg
Staphylococcal Infection
Gonalef® (Follitropin alfa)
Infertility
peg-Interferon alfa-2a
Hepatitis C, Chronic
Calderasib
Non-small Cell Lung Cancer
ZOSTAVAX
Herpes Zoster
(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Condylomata Acuminata
Peginterferon
Multiple Myeloma
H2 Receptor Antagonist
Non-small Cell Lung Cancer (NSCLC)
RotaTeq®
Meningitis, Meningococcal
sitagliptin phosphate
Type 2 Diabetes
Infliximab
Psoriasis
Boceprevir (BOC)
Chronic Hepatitis C
Intismeran autogene
Bladder Cancer
MK0869, aprepitant
Postoperative Nausea and Vomiting
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks
Foot Infections in Diabetic Patients
Naproxen
Endometriosis-related Pain
Ertugliflozin 15 mg
Type 2 Diabetes Mellitus
Pembrolizumab/Vibostolimab Co-Formulation
Small Cell Lung Carcinoma
Voriconazole
Aspergillosis
Short ragweed pollen allergen extract
Rhinitis, Allergic, Seasonal
MK0803, lovastatin
Hypercholesterolemia
fidaxomicin
Clostridium Difficile-Associated Diarrhea (CDAD)
MK-3475A
Non-small Cell Lung Cancer
Prevenar 13™
Pneumococcal Infections
Trifluridine-Tipiracil
Gastroesophageal Cancer
Rescue medication
Non-Muscle Invasive Bladder Cancer
Tisotumab Vedotin
Cervical Cancer
Metformin IR
Type 2 Diabetes Mellitus
Pembrolizumab (K)
Breast Cancer
losartan potassium
Hypertension
niacin (+) laropiprant
Hypercholesterolemia
TAS-102 (trifluridine and tipiracil)
Colorectal Neoplasms
Diquafosol tetrasodium ophthalmic solution, 2%
Dry Eye Disease
favezelimab/pembrolizumab
Hodgkin Lymphoma
Golimumab
Spondylitis, Ankylosing
zoster vaccine live (ZOSTAVAX™)
Herpes Zoster
TAS-102
Colorectal Cancer
Infliximab + methotrexate (MTX)
Arthritis, Rheumatoid
Montelukast
Asthma
anacetrapib
Coronary Heart Disease (CHD)
Zoster Vaccine Live
Herpes Zoster
Epirubicin
Triple Negative Breast Neoplasms
Enlicitide
Hyperlipidemia
Pergoveris®
Infertility
Meropenem
Healthcare-Associated Pneumonia
Suvorexant Low Dose (LD)
Primary Insomnia
ER niacin/laropiprant
Diabetes Mellitus Type 2
Gefapixant 15 mg BID
Chronic Cough
Standard of Care (SOC)
Solid Tumors
Enalapril
Hypertension
Tedizolid phosphate
Acute Bacterial Skin and Skin Structure Infections
r-hCG
Infertility
Ceftolozane/Tazobactam
Complicated Intra-Abdominal Infection
hMG
Infertility
Grazoprevir + Elbasvir
Hepatitis C Infection
dorzolamide hydrochloride (+) timolol maleate
Glaucoma
Cetuximab + concomitant boost radiotherapy
Squamous Cell Carcinoma of the Head and Neck
rofecoxib
Prostate Cancer
SC golimumab
Arthritis, Rheumatoid
ProQuad®
Measles
Sitagliptin 100 mg
Type 2 Diabetes Mellitus
Voglibose
Diabetes Mellitus, Non-Insulin-Dependent
ER-niacin
Primary Hypercholesterolaemia
MK-1293
Type 1 Diabetes Mellitus
Bisoprolol/Amlodipine (Bisoprolol failed group)
Hypertension
PAR-101/OPT-80
Clostridium Infections
ZOSTAVAX™
Herpes Zoster
cetuximab + cisplatin + vinorelbine
Non Small Cell Lung Cancer (NSCLC)
RotaTeq™, rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
Papillomavirus Infections
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Type 2 Diabetes Mellitus (T2DM)
ER niacin (+) laropiprant (ERN/LRPT)
Dyslipidemia
Infliximab + methotrexate (IFX + MTX)
Arthritis, Psoriatic
MK0966; Rofecoxib / Duration of Treatment: 156 weeks
Colorectal Adenoma
Rebif New Formulation + prophylactic Ibuprofen
Relapsing Multiple Sclerosis
Imipenem
Bacterial Pneumonia
Vorinostat
Mesothelioma
PPSV23
Pneumococcal Disease
L50/H12.5/A5
Hypertension
Boceprevir
Chronic Hepatitis C Genotype 1
Esmirtazapine
Insomnia
MK0826, /Duration of Treatment : 8 Weeks
Complicated Intra-Abdominal Infections
PNEUMOVAX™23
Pneumococcal Infections
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Head and Neck Cancer
Finasteride
Enlarged Prostate
raltegravir
HIV
MK0826, ertapenem sodium
Infections
sugammadex
Neuromuscular Blockade
hydrochlorothiazide (HCTZ)
Hypertension
pembrolizumab
Colorectal Neoplasms
Ertapenem sodium
Infection; Diabetic Foot
loratadine; montelukast
Rhinitis, Allergic, Seasonal
Recombinant Human Papillomavirus Nonavalent Vaccine
AIDS-Related Human Papillomavirus Infection
Pembrolizumab (+) Berahyaluronidase alfa
Lung Cancer
Tedizolid Phophate
Skin Diseases, Infectious
Isentress®
HIV Infections
MK0826, ertapenem sodium / Duration of Treatment: 14 Days
Infection
MK0507A, dorzolamide hydrochloride (+) timolol maleate
Glaucoma
Sitagliptin
Hyperlipidemia
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
Osteoporosis
raltegravir potassium
HIV Infections
Vancomycin (or equivalent)
Acute Hematogenous Osteomyelitis
Insulin
Type 2 Diabetes Mellitus
Ezetimibe
Hypercholesterolemia
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
Vomiting
Calcium supplement
Osteoporosis
pneumococcal 23v polysaccharide vaccine
Pneumococcal Infection
niacin (+) laropiprant (+) simvastatin
Primary Hypercholesterolemia
Modified Process Hepatitis B Vaccine (Experimental)
Hepatitis B
rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
sitagliptin/metformin
Type 2 Diabetes Mellitus
Grazoprevir/Elbasvir
Hepatitis C
MK-6072
Clostridium Difficile Infection
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
Papillomavirus Infections
V212
Herpes Zoster
laropiprant/niacin (MK0524A)
Hypercholesterolemia
Riociguat (Adempas, BAY63-2521)
Hypertension, Pulmonary
9vHPV vaccine
Papillomavirus Infections
Gonal-f®
Assisted Reproductive Techniques
Dexamethasone 4 mg
Non-Small-Cell Lung Carcinoma
COL-1620
Luteal Hormone Supplementation in In-vitro Fertilization
losartan potassium (+) hydrochlorothiazide
Hypertension
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine
Diphtheria
Open-label Metformin
Type 2 Diabetes
Acid Nicotinique
Acute Coronary Syndrome (ACS)
Interferon-alpha2b - 1 year
Melanoma
Pre-treatment with rLH (Luveris 75 IU),
Infertility, Female
Varicella-zoster vaccine
Herpes Zoster
V501
Human
Preladenant
Parkinson Disease
Olaparib
Ovarian Cancer
Lantus™
Type 2 Diabetes Mellitus
Opevesostat
Prostate Cancer Metastatic
FTC/TDF + EFV or LPV/R +T20
HIV Infections
Sotatercept
Pulmonary Arterial Hypertension
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
Hepatitis C, Chronic
7-valent pneumococcal-CRM197 conjugate vaccine
Otitis Media
budesonide and montelukast
Obstructive Sleep Apnea
Avonex®
Multiple Sclerosis, Relapsing-Remitting
Corifollitropin Alfa
Infertility, Female
Bezlotoxumab
Clostridium Difficile Infection
Metronidazole
Complicated Intra-abdominal Infections
Raptiva
Moderate to Severe Psoriasis
Pembrolizumab 400 mg
Small Cell Lung Cancer
mRNA-1273 Vaccine
Papillomavirus Infections
PCV20
Pneumococcal Infection
Rescue Medications
Cervical Cancer
MTX
Arthritis, Rheumatoid
Elbasvir
Hepatitis C
Etoricoxib
Knee Osteoarthritis
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Cervical Cancer
V920 Consistency Lot A
Prevention of Ebola Infection
raltegravir (Isentress)
HIV Infections
week 24
Peripheral Spondyloarthritis
Peginterferon alfa-2a
Hepatitis C, Chronic
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Letermovir
Cytomegalovirus Infection
Ertugliflozin
Type 2 Diabetes Mellitus
0.9% sodium chloride (NaCl)
Anesthesia
Peginterferon alfa-2b
Carcinoma, Hepatocellular
V232 Modified Process Hepatitis B Vaccine: Lot A
Hepatitis B Infection
Ipragliflozin
Type 2 Diabetes Mellitus
PCV13
Pneumococcal Infections
Rocuronium bromide
Anesthesia
IMI/REL
Suspected or Documented Gram-negative Bacterial Infection
INFANRIX™ hexa
Bacterial Infections
Letermovir 480 mg once daily
Kidney Transplant; Complications
PR5I
Neisseria Meningitidis
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)
Varicella
Anacetrapib 100 mg
Hypercholesterolemia
MK0966, rofecoxib
Postoperative Pain
Cladribine (MAVENCLAD®)
Advanced Multiple Sclerosis
Posaconazole oral suspension
Mycoses
Tobramycin
Bacterial Conjunctivitis
Delstrigo
HIV-1-infection
ezetimibe with simvastatin
Hypercholesterolemia
Pegylated interferon alfa-2b
Hepatitis C
Follitropin alfa liquid formulation
Infertility
Gliclazide
Type 2 Diabetes Mellitus
Micronised Progesterone
Infertility
Imipenem+Cilastatin/Relebactam
Complicated Intra-abdominal Infection
MK-0524A
Hypercholesteremia
Basal Insulin
Type 2 Diabetes Mellitus
Ezetimibe + Atorvastatin
Hypercholesterolemia
Supportive care measures
Non-small Cell Lung Cancer (NSCLC)
Golimumab 50 mg SC
Arthritis
sac-TMT
Non-small Cell Lung Cancer
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Chronic Hepatitis C
Org 50081
Insomnia
ezetimibe (plus simvastatin)
Atherosclerosis
Doravirine
HIV-1
Telcagepant
Migraine
Epacadostat
Gastric Adenocarcinoma
rolofylline
Heart Failure, Congestive
ZOSTAVAX™ (concomitant)
Herpes Zoster
HBVAXPRO™
Hepatitis B
VARIVAX™
Varicella
Lenvatinib
Non-small Cell Lung Cancer
SC Tulisokibart
Ulcerative Colitis
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Human Papillomavirus Infection
Estrogens
Infertility
V116
Pneumococcal Infection
Omarigliptin
Type 2 Diabetes Mellitus
Vericiguat
Heart Failure
MR Prednisone
Rheumatoid Arthritis
DAPTACEL™
Bacterial Infections
Pembrolizumab 200 mg
Non-Small-Cell Lung Carcinoma
Enpatoran
Systemic Lupus Erythematosus (SLE)
V260
Rotavirus Gastroenteritis
IMI/REL FDC
Hospital-Acquired Bacterial Pneumonia
MK0974 50 mg
Migraine
sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
Type 2 Diabetes Mellitus
Combination of (a) pegylated interferon alfa-2b and (b) rebetol
Liver Transplantation
Gefapixant 45 mg twice daily (BID)
Chronic Cough
Patritumab Deruxtecan
Malignant Neoplasm
Epinephrine
Malignant Neoplasms of Male Genital Organs
Vicriviroc
HIV Infections
Simvastatin 20 mg daily
Cardiovascular Disease
alendronate with cholecalciferol
Osteoporosis
MK-8748
Diabetic Retinopathy
Molnupiravir
Coronavirus Disease (COVID-19)
Gefapixant
Chronic Cough
ertapenem sodium (MK0826)
Urinary Tract Infection
Pegylated liposomal doxorubicin (SCH 200746)
Breast Cancer
peginterferon alfa-2b (SCH 54031)
Chronic Hepatitis C
Pembrolizumab SC
Non-Small Cell Lung Cancer
MK0869, aprepitant / Duration of Treatment: 3 days
Nausea
ISL
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Indinavir sulfate
HIV Infections
TR-701 FA
Skin and Subcutaneous Tissue Bacterial Infections
Ridaforolimus
Sarcoma
V503
Papillomavirus Infections
Gardasil
Papillomavirus Infections
Neostigmine
Anesthesia
5-Fluorouracil
Uterine Cervical Neoplasms
CB-183,315
Clostridium Difficile Infection
Saizen®
Fibromyalgia
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Measles
ceftriaxone sodium
Infection
PCV15
Pneumonia, Pneumococcal
mFOLFOX6
Colorectal Carcinoma
eribulin
Metastatic Triple Negative Breast Cancer
Sitagliptin (MK0431)
Diabetes Mellitus, Type II
Sitagliptin 50 mg
Type 2 Diabetes Mellitus
Cisplatin 100 mg/m^2
Head and Neck Neoplasms
Efavirenz
HIV Infections
Enlicitide Decanoate
Hypercholesterolemia
Odanacatib
Osteoporosis Postmenopausal
pegylated interferon alpha-2b
Hepatitis B, Chronic
neostigmine and glycopyrrolate or atropine
Neuromuscular Blockade
Preservative-Free Tafluprost or vehicle
Glaucoma
Preladenant 2 mg tablet
Parkinson Disease
V419
Bacterial Infections
Suvorexant
Insomnia
Recombinant human luteinizing hormone (r-hLH)
Hypogonadism
Rocuronium
Anesthesia, General
Experimental: V503
Cervical Cancer
vaniprevir
Hepatitis C, Chronic
Peginterferon alfa-2b (PegIntron, SCH 54031)
Hepatitis D, Chronic
RNF
Multiple Sclerosis
H1 receptor antagonist
Ovarian Cancer
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
Cervical Cancer
Telcagepant potassium 150 mg
Migraine
Cetrorelix acetate
Polycystic Ovarian Syndrome
Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
Hepatitis A Virus Infection
Pegylated interferon alfa-2b (SCH 54031)
Hepatitis C, Chronic
Sugammadex 0.5 mg/kg
Anesthesia
VARIVAX® PE34 Process
Varicella
INS365 Ophthalmic Solution
Keratoconjunctivitis Sicca
Rotavirus vaccine
Bacterial Infections
MK-8591A
HIV-1 Infection
Belzutifan
Renal Cell Carcinoma
Interferon-beta-1a
Hepatitis C
Dinaciclib
Chronic Lymphocytic Leukemia (CLL)
Vorapaxar 2.5 mg
Cerebral Infarction
Rocurium
Anesthesia, General
Vericiguat tablet
Heart Failure
ATRIPLA™
Human Immunodeficiency Virus (HIV)
MK-1045
Lymphoma, Non-Hodgkin
Glipizide
Diabetes Mellitus, Type 2
Surotomycin
Clostridium Difficile Infection
Blinatumomab
B-cell Acute Lymphoblastic Leukemia
Anagrelide
Essential Thrombocythemia
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Primary Biliary Cholangitis
Arm A: Pemetrexed Cisplatin
Non Small Cell Lung Cancer
EVX-01
Melanoma Stage IV
PembroRT
Non-small Cell Lung Cancer, NSCLC
Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
Recurrent Mantle Cell Lymphoma
MK1903
Dyslipidemia
MK-2206
PANCREAS
Peginterferon alfa-2a (Peg-IFN)
Hepatitis C, Chronic
denufosol tetrasodium Inhalation Solution
Cystic Fibrosis
CXA-101
Complicated Urinary Tract Infection
MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks
Hypercholesterolemia
pegylated interferon
Chronic Hepatitis C
Multiple low dose cyclophosphamide
Multiple Myeloma
Azacitadine
Acute Myeloid Leukemia
Cisplatin (TP)
Squamous Cell Carcinoma of the Hypopharynx
pIL-12
Melanoma
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Solid Tumor, Adult
LY3537982
Carcinoma, Non-Small-Cell Lung
Butantan - DV
Dengue
denufosol tetrasodium (INS37217)
Cystic Fibrosis
OPT-80
Diarrhea
Dalotuzumab
Carcinoma, Non-small-cell Lung
MK-8777
Depression
ARQ 197
Pancreatic Neoplasms
ARQ 501
Cancer
Robatumumab
Colorectal Cancer
ADL5945 0.1 mg
Opioid Induced Constipation
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
Diabetes Mellitus, Type II
M5717 330 mg
Acute Malaria
Vibostolimab
Melanoma
MK0493
Obesity
MK0812 / Duration of Treatment: 12 Weeks
Arthritis, Rheumatoid
INS37217 Nasal Spray
Perennial Allergic Rhinitis
MK0777
Generalized Anxiety Disorder
Uprifosbuvir
Hepatitis C
Pneumococcal Conjugate Vaccine (V114)
Pneumococcal Infections
V114 Aluminum-adjuvanted
Pneumococcal Infections
Vibostolimab/Pembrolizumab
Carcinoma, Renal Cell
MK-3120
Urothelial Carcinoma
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
Type 2 Diabetes Mellitus
Navarixin
Solid Tumors
Daptomycin for Injection
Bacteremia
UFOX + Cetuximab
Previously Untreated Metastatic Colorectal Cancer
Ritonavir
HIV Infections
Raludotatug Deruxtecan (R-DXd)
Gastrointestinal Cancer
Tepotinib
Non-small Cell Lung Cancer
MK-3795
VHL Gene Mutation
V114 Lot 1
Pneumococcal Infections
adavosertib
Ovarian Cancer
MK0249
Attention-Deficit/Hyperactivity Disorder (ADHD)
MK-8435 (Org 25935) 4-8 mg
Schizophrenia
MK-6096
Migraine
Pembrolizumab/vibostolimab coformulation
Bladder Cancer
irinotecan hydrochloride
Metastatic Colorectal Cancer
MK-0941
Type 2 Diabetes Mellitus
Vaniprevir 600 mg b.i.d.
Hepatitis C, Chronic
IDX719
Hepatitis C, Chronic
MK2295
Pain, Postoperative
Quavonlimab
Advanced Solid Tumors
MK-1167
Alzheimer Disease
SCH 530348
Arterial Obstructive Diseases
Epinastine Nasal Spray
Seasonal Allergic Rhinitis
Merck L-830982
Schizophrenia
Avelumab
Squamous Non-Small Cell Lung Cancer
MK-4830
Carcinoma, Non-Small-Cell Lung
zoster vaccine live (Oka/Merck)
Shingles
Raludotatug Deruxtecan
Ovarian Cancer Recurrent
Coformulation favezelimab/pembrolizumab
Esophageal Squamous Cell Carcinoma (ESCC)
Fosaprepitant
Chemotherapy-induced Nausea and Vomiting
Gefapixant 45 mg
Chronic Cough
Farnesyl Protein Transferase Inhibitor
Leukemia
ADL5859
Peripheral Neuropathy
MK2461
Neoplasm
MK0991, caspofungin acetate
Aspergillosis
SCH 486757
Cough
Tecemotide (L-BLP25)
Lung Neoplasms
measles, mumps, and rubella virus vaccine live
Measles
AS900672-Enriched 50 microgram (mcg)
Infertility
Cilengitide
Carcinoma, Non-Small-Cell Lung
ecallantide
Bloodloss
Pembrolizumab (neoadjuvant)
Lung Neoplasm Malignant
MK0518
HIV Infections
ADL5945 0.25 mg
Constipation
ENB003
Cancer
MK-5684
Malignant Neoplasm
Attenuvax
HIV Infections
TU2218 + KEYTRUDA® (Pembrolizumab)
Solid Tumor
Ertugliflozin 1 mg
Diabetes Mellitus, Type 2
M5049 low dose
Systemic Lupus Erythematosus
Pegylated Interferon Alfa
Chronic Hepatitis C
KW-3902IV
Heart Failure, Congestive
Favezelimab
Advanced Non-Small Cell Lung Cancer
tildrakizumab
Psoriasis
SCH 900538
Seasonal Allergic Rhinitis
EBR/GZR FDC Tablet
HCV Infection
MK0916
Diabetes Mellitus, Type 2
V160
Cytomegalovirus (CMV) Infections
MK-2140 (zilovertamab vedotin)
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Cabazitaxel
Prostatic Neoplasms, Castration-Resistant
L-dopa
Parkinson Disease
MK0364
Obesity
Single low dose cyclophosphamide
Carcinoma, Non-Small-Cell Lung
MK-8189
Schizophrenia, Acute Episode
Recombinant human growth hormone (r-hGH)
Hypochondroplasia
CyPep-1
Advanced Head and Neck Squamous Cell Carcinoma
Stavudine
HIV Infections
Pembrolizumab and Lenvatinib
Hepatocellular Carcinoma
Boserolimab
Small Cell Lung Cancer
2 NRTIs
Human Immunodeficiency Virus (HIV) Infection
PegIFN-2b
HIV Infections
PegIntron (peginterferon alfa-2b)
Hepatitis C, Chronic
Relebactam 250 mg
Intra-abdominal Infections
Atorvastatin/niacin extended-release
Carotid Atherosclerosis
Rebif
Multiple Sclerosis
MK-0873
Rheumatoid Arthritis
Matuzumab
Esophageal Cancer
V504
Cervical Cancer
imipenem/cilastatin 500 mg
Urinary Tract Infections
cetuximab, cisplatin
Breast Neoplasm
Interferon beta-1a
Alzheimer's Disease
V114 Medium Dose
Pneumococcal Infections
V181 High-Potency Level
Dengue Disease
cyclophosphamide (CPA)
Rectal Cancer
Biltricide (racemate praziquantel) oral tablets
Schistosomiasis
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
SCH 900636
Depressive Disorders
Pegylated Lyposomal Doxorubicin
Breast Neoplasm
MK0782
Stomach Ulcer
EMD 525797 250 mg
Metastatic Colorectal Cancer
TR701 FA
Major Cutaneous Abscess
Doravirine, Tenofovir, Lamivudine - Blinded
HIV-1
V940
Squamous Non-small Cell Lung Cancer
R-DXD
Lung Neoplasm
Efinopegdutide
Metabolic Dysfunction-Associated Steatotic Liver Disease
PRA023 IV
Crohn Disease
Zolinza (vorinostat)
Lymphoma
Metolazone
Heart Failure
Suvorexant 20 mg
Delirium in Old Age
ST-067
Cancer
Miransertib
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
MK-0893
Diabetes Mellitus, Type 2
ZA
Breast Cancer
L-756423
HIV Infections
timolol/dorzolamide combination
Glaucoma
AO-176
Solid Tumor
Esmeron®
Neuromuscular Blockade
NM283 plus Peg-IFNα-2a
Chronic Hepatitis C
Gefapixant 50 mg
Asthma
MK-2060
End-Stage Renal Disease
IDX184
Chronic Hepatitis C Infection
Pleconaril
Asthma
KVA12123 - Dose Escalation
Cancer
Gocatamig
Small-Cell Lung Cancer
MK-1200
Advanced Solid Tumors
SCH 727965
Breast Neoplasms
V114-A
Pneumococcal Infections
IFN beta 1a 44 mcg TIW
Multiple Sclerosis
Pegylated Liposomal Doxorubicin
Breast Neoplasm
Tepotinib 300 mg
Carcinoma, Hepatocellular
Lenvatinib Capsules
Hepatocellular Carcinoma
Avastin
High-grade Serous Ovarian Carcinoma
Atacicept
Rheumatoid Arthritis
Vibegron
Urinary Bladder, Overactive
Org 34517
Depression
MK-1029
Asthma
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
HIV-1 Infection
CRS-207
Metastatic Pancreatic Adenocarcinoma
Lenvatinib Oral Product
Merkel Cell Carcinoma
Coformulated favezelimab/pembrolizumab
Metastatic Urothelial Carcinoma
val-mCyd
Chronic Hepatitis C
Gefapixant 100 mg
Refractory Chronic Cough
Radium-223
Prostate Cancer
Vicriviroc 30 mg
HIV Infections
valopicitabine
Chronic Hepatitis C
MK0677
Alzheimer's Disease
Interferon-beta-1a, 44 microgram
Ulcerative Colitis
MK0991, caspofungin acetate/Duration of Treatment: variable
Candidiasis
TRUVADA®
HIV Infections
Antihistamine
Esophageal Squamous Cell Carcinoma
Oral testosterone undecanoate (Andriol)
Hypogonadism
Dalantercept
Squamous Cell Carcinoma of the Head and Neck
Sugar Pill
Osteoarthritis of the Knee
Sotatercept 0.3 mg/kg
Hypertension, Pulmonary
Vorapaxar
Atherosclerosis
Docetetaxel
Carcinoma, Non-Small-Cell Lung
Pertuzumab
Breast Neoplasms
epinastine 0.1%
Allergic Rhinitis
MK-8998
Schizophrenia
ATX-MS-1467
Multiple Sclerosis
Dalantercept plus sorafenib
Advanced Adult Hepatocellular Carcinoma
Nelfinavir mesylate
HIV Infections
AR51 (12, 10)
Bacterial Infections; Virus Diseases
EV
Bladder Cancer
MK0974
Migraine
diphenhydramine
Carcinoma, Non-Small-Cell Lung
MK-8616
Neuromuscular Blockade
Pembrolizumab 25 MG/ML [KEYTRUDA®]
Advanced Solid Tumor Malignancy
Benznidazole
Chagas Disease
FF-10832
Advanced Urothelial Carcinoma
raltegravir and etravirine
HIV-1 Infection
Ertugliflozin 25 mg
Diabetes Mellitus, Type 2
MK8141
Hypertension
MK0822A
Vitamin D Deficiency
MK0633
Atherosclerosis
MK633
Chronic Obstructive Pulmonary Disease (COPD)
Doxorubicin hydrochloride
Breast Neoplasms
r-FSH
Ovarian Stimulation
Enclitide Chloride
Hypercholesterolemia
Pimicotinib
Tenosynovial Giant Cell Tumor
coformulation pembrolizumab/quavonlimab
Small Cell Lung Carcinoma
ATRA
Melanoma
MK-2214
Early Alzheimer's Disease
Dabrafenib
Melanoma
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
Flushing
ridaforolimus (MK8669)
Prostate Cancer
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
B-cell Lymphoma
Rolapitant Dose 1
Postoperative Nausea and Vomiting
MK0359
Pulmonary Disease, Chronic Obstructive
MK0524
Seasonal Allergies
peginterferon alfa 2b
Hepatitis C, Chronic
TS-1
Gastric Cancer
Rescue
Type II Diabetes Mellitus
Tivantinib
Advanced Solid Tumors
Recombinant human follicle stimulating hormone (r-hFSH)
Infertility
Itraconazole
Chronic Hepatitis C
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
HPV Infections
Pegylated Interferon (peg-IFN)
Hepatitis C
Ifinatamab Deruxtecan (I-DXd)
Small Cell Lung Cancer
Ruzasvir
Hepatitis C
Letermovir oral granules
Cytomegalovirus (CMV) Infection
Raltegravir Film-coated Tablet
HIV Infection
teicoplanin
Osteomyelitis
SCH 900271 15mg
Primary Hypercholesterolemia
MK5757
Schizophrenia
Samatasvir
Chronic Hepatitis C Virus
Ulevostinag
Head and Neck Squamous Cell Carcinoma (HNSCC)
ARQ 501 in combination with gemcitabine
Pancreatic Cancer
V205C, measles, mumps, and rubella virus vaccine live
Measles
medroxyprogesterone acetate tablets OR megestrol acetate
Endometrial Cancer
Posaconazole IV 6 mg/kg
Invasive Fungal Infection
Islatravir
HIV-1 Infection
RSV A Memphis 37b
Respiratory Syncytial Virus
SCH 619734
Cough
ADL5747
Osteoarthritis of the Knee
TR-701 200 mg
Skin Diseases, Infectious
Efinopegdutide 20 mg/mL
Nonalcoholic Fatty Liver Disease
Sitagliptin 25 mg
Glucose Intolerance
ADL5859 30 mg
Acute Pain
MK3207- 2.5 mg
Migraine
Grazoprevir (GZR)
Hepatitis C Virus
I-DXd
Esophageal Squamous Cell Carcinoma
SCH 56592
Onychomycosis
MK0524A, /Duration of Treatment : 8 Weeks
Flushing
Grazoprevir/Elbasvir FDC
Hepatitis C
MK-5442
Osteoporosis
Caspofungin
Candidiasis, Esophageal
M5717 60 mg
Malaria Infection
SCH 497079
Obesity
tretinoin
Acute Myeloid Leukemia
MK0826, ertapenem sodium /Duration of Treatment: 14 Days
Urinary Tract Infections
MK-0482
Carcinoma, Non-Small-Cell Lung
MK0736
Hypertension
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Papillomavirus Infections
MK0686
Pain, Postoperative
MK-6213
Hypercholesterolemia
VigantOL oil plus interferon beta-1a (Rebif)
Relapsing-Remitting Multiple Sclerosis
Vicriviroc maleate
HIV
MK-8690
Colitis Ulcerative
Olaparib 400 mg
Metastatic Castration-Resistant Prostate Cancer
MK0429
Post-Menopausal Osteoporosis
Letermovir Pill
CMV
Ensifentrine
COPD
MK-0634 50 mg
Urinary Incontinence
ridaforolimus + dalotuzumab
Breast Cancer
rolofyline
Congestive Heart Failure
Posaconazole IV
Invasive Aspergillosis
MK-1029 150 mg
Asthma
r-hFSH
Infertility
Cilengitide 2000 mg once weekly
Squamous Cell Cancer
Navarixin 10 mg
Psoriasis
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks
HIV Infections
PR51 (3, 10)
Bacterial Infections; Virus Diseases
carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
Squamous Cell Carcinoma of Larynx
Methotrexate 1 GM Injection
Gestational Trophoblastic Neoplasias (GTN)
TEW-7197
Metastatic Colorectal Cancer
M9140
Solid Tumors
Imprime PGG
Malignant Neoplasm of Breast
Crinone 8%
Postmenopausal Endometrium
Mirdametinib
Central Nervous System Tumors
Bintrafusp Alfa
Nasopharyngeal Carcinoma
Pembrolizumab (Keytruda)
Thyroid Cancer
Axatilimab
TNBC - Triple-Negative Breast Cancer
Alendronate
Osteoporosis
Nirogacestat
Tumor
Boceprevir, Peg-interferon alfa 2b and Ribavirin
HCV Coinfection
Peg-Interferon α-2b or Peg-Interferon α-2a
HCV Infection
Pembrolizumab Injection [Keytruda]
Malignant Neoplasm of Breast
ATG-022
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
ART Intensification
HIV-1 Infection
Allogeneic cytomegalovirus-specific T cells
Glioblastoma Multiforme
ADV/HSV-tk
Metastatic Non-small Cell Lung Cancer
Testosterone Enanthate
Male Hypogonadism
BET Bromodomain Inhibitor ZEN-3694
Castration-Resistant Prostate Carcinoma
olaparibp, embro
Ovarian Cancer
aprepitant, ondansetron, dexamethasone
Nausea
azacytidine
Lymphoma
galinpepimut-S
Acute Myelogenous Leukemia
Neoadjuvant Pembrolizumab
Breast Cancer
Entereg
Laparoscopic Colonic Resection
D-1553
Solid Tumor, Adult
Bilastine
Seasonal Allergic Rhinitis
Q901
Advanced Cancer
5HT3
Chemotherapy-Induced Nausea and Vomiting
FOLFIRI + Cetuximab
Metastatic Colorectal Cancer
Prednisone 5Mg
Prostate Cancer Aggressiveness
GVAX Pancreatic Cancer Vaccine
Pancreatic Cancer
Lenvatinib Mesylate
Kidney Cancer
Polatuzumab vedotin
Lymphoma, Large B-Cell, Diffuse
IMGN853
Endometrial Cancer
GAd-209-FSP low dose
Solid Tumor, Adult
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
Metastatic Malignant Neoplasm in the Liver
Vinblastine
Classical Hodgkin Lymphoma
Defactinib
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
ACE-536
Beta-Thalassemia
Paclitaxel 45 mg/m^2
Non-small Cell Lung Cancer
Pembrolizuma
Metastatic Breast Cancer
Vorinostat Velcade Dexamethasone
Multiple Myeloma
Pembrolizumab with All-Trans Retinoic Acid
Stage IV Melanoma
Elpipodect
Schizophrenia
CXA-101/ tazobactam and metronidazole
Complicated Intra-abdominal Infection
ABL103
Solid Tumors
pembrolizumab, gemcitabine and cisplatin
Bladder Cancer
Ezetimibe/Simvastatin
Type 1 Diabetes Mellitus
R-CHOP Protocol
B Cell Lymphoma
MK-3475 (neoadjuvant)
Cancer of Head and Neck
Bemcentinib
Lung Cancer Metastatic
Pembrolizumab 200 mg IV infusion
Stage IIIB(N2) Non-small Cell Lung Cancer
Poly-ICLC
Metastatic Colon Cancer
Pegylated Interferon alpha 2b
HIV-1 Infection
UFT
Metastatic Colorectal Cancer
Vinblastine Sulfate
Stage II Bladder Cancer AJCC v8
DPX-Survivac
Relapsed Diffuse Large B-cell Lymphoma
Bacillus Calmette-Guérin (BCG)
Bladder Cancer
HIF-2alpha Inhibitor PT2385
Recurrent Glioblastoma
pTVG-HP
Castration-resistant Prostate Cancer
emtricitabine / tenofovir disoproxil fumarate / raltegravir .
HIV-2 Infection
GSK2636771
Melanoma and Other Malignant Neoplasms of Skin
Human Papillomavirus vaccine
Cervical High Grade Squamous Intraepithelial Lesion
Tinodasertib
Metastatic Colorectal Cancer
Azithromycin ophthalmic solution, 1%
Blepharitis
Aprepitant/Ramosetron/Dexamethasone
Chemotherapy-Induced Nausea and Vomiting
Zepatier
End Stage Renal Disease
Prednisone or prednisolone
Metastatic Castration-resistant Prostate Cancer
Sitagliptin + Metformin
Pre-diabetes
ACP-196 in combination with pembrolizumab
Metastatic Urothelial Carcinoma
Letermovir 480 MG [Prevymis]
Cytomegalovirus Infections
Cefepime
Other Infectious Diseases
Pegzilarginase
Small-cell Lung Cancer
Spevatamig (PT886)
Gastric or Gastroesophageal Junction Adenocarcinoma
Pembrolizumab 25 MG/1 ML Intravenous Solution
Metastatic Uveal Melanoma
MK-1775 and carboplatin
Epithelial Ovarian Cancer
EIDD-2801
SARS-CoV 2
Gemox, Cetuximab
Advanced Biliary Cancer
Encorafenib Oral Capsule + Cetuximab
Colorectal Cancer
cetuximab, cisplatin, capecitabine
Gastric Cancer
Epclusa
Lung Diseases
acetominophen
Migraine
FLOT
Esophagogastric Adenocarcinoma
Afatinib
Carcinoma, Non-Small-Cell Lung
Hyperpolarized 13C-Pyruvate
Neuroendocrine Tumors
Cyklokapron(R)
Bloodloss
IMG-7289
Thrombocythemia, Essential
cis/carboplatin and etoposide
Small Cell Lung Cancer (SCLC)
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)
Ebola Virus Disease
Molnupiravir 200 mg
SARS-CoV-2 Infection, COVID-19
MK-0646
Neuroendocrine Tumors
Ibutamoren Mesylate (MK-0677)
Fibromyalgia
Pembrolizumab, Cetuximab
HNSCC
TILT-123
Platinum-refractory Ovarian Carcinoma
Capecitabine/ 5-FU
Colorectal Cancer
Cetuximab (Erbitux)
Cancer
FOLFOX-4+cetuximab
Colorectal Cancer
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
Cancer Survivor
Nesuparib
Endometrial Cancer
Odetiglucan
Colorectal Adenocarcinoma Metastatic in the Liver
rVSVΔG-ZEBOV-GP, V920
Ebola Virus Disease
Ataluren + Pembrolizumab
Colorectal Cancer
Cyclophosphamide 50mg
Metastatic Breast Cancer
Lonafarnib
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ULO | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - | - |
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® | Phase 3 | Measles | - | - |
100 mg clindamycin /800 mg ketoconazole vaginal ovule | Phase 3 | Vaginosis, Bacterial | - | - |
Telcagepant 140 mg | Phase 3 | Migraines | - | - |
Telcagepant 300 mg soft gel capsules | Phase 3 | Migraine | - | - |
CXA-201 | Phase 3 | Complicated Urinary Tract Infection | - | - |
Rotarix™ | Phase 3 | Pneumococcal Infections | - | - |
QIV | Phase 3 | Pneumonia, Pneumococcal | - | - |
Acetaminophen/Paracetamol | Phase 3 | Migraine Disorders | - | - |
MK-3415 | Phase 3 | Clostridium Difficile Infection | - | - |
Leucovorin/ levoleucovorin | Phase 3 | Metastatic Colorectal Cancer | - | - |
epinastine nasal spray, low concentration, low dose volume | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Letermovir tablet | Phase 3 | Cytomegalovirus Infection | - | - |
peginterferon alfa-2b (PEG2b) (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
Prulifloxacin | Phase 3 | Acute Gastroenteritis in Adult Travelers | - | - |
Efalizumab | Phase 3 | Moderate to Severe Psoriasis | - | - |
Suvorexant High Dose (HD) | Phase 3 | Primary Insomnia | - | - |
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Phase 3 | Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer | - | - |
Valganciclovir | Phase 3 | CMV Disease | - | - |
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) | Phase 3 | Intra-abdominal Infection | - | - |
Uridine 5'-Triphosphate (UTP) Solution for Inhalation | Phase 3 | Lung Cancer | - | - |
S-1 | Phase 3 | Gastric Cancer | - | - |
Glycopyrrolate | Phase 3 | Surgical Procedures, Elective | - | - |
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) | Phase 3 | Rotavirus | - | - |
MK0966 / Duration of Treatment: 1 Days | Phase 3 | Pain, Postoperative Arthroscopy | - | - |
MK0524A, /Duration of Treatment : 4 Weeks | Phase 3 | Flushing | - | - |
Alviompan | Phase 3 | Bowel Dysfunction | - | - |
taranabant | Phase 3 | Smoking | - | - |
regorafenib | Phase 3 | Colorectal Cancer | - | - |
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks | Phase 3 | Measles | - | - |
Rebif® New Formulation (IFN-beta-1a, RNF) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years | Phase 3 | Cervical Cancer | - | - |
sitagliptin phosphate (+) metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Peginterferon alfa-2b (PEG) | Phase 3 | Hepatitis C, Chronic | - | - |
Cladribine Low Dose | Phase 3 | Generalized Myasthenia Gravis | - | - |
Rocuronium bromide (Zemuron) | Phase 3 | Anesthesia | - | - |
Colistimethate sodium (CMS) | Phase 3 | Bacterial Infections | - | - |
Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Phase 3 | Cervical Cancer | - | - |
ART | Phase 3 | HIV-1 Infection | - | - |
Acarbose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pegylated interferon alfa-2b (PegIntron) | Phase 3 | Hepatitis B, Chronic (CHB) | - | - |
Sitagliptin plus metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
V110, pneumococcal vaccine polyvalent | Phase 3 | Healthy | - | - |
Linezolid | Phase 3 | Pneumonia | - | - |
Zanzalintinib | Phase 3 | Renal Cell Carcinoma | - | - |
liposomal doxorubicin | Phase 3 | Breast Neoplasms | - | - |
diquafosol tetrasodium (INS365) ophthalmic solution | Phase 3 | Dry Eye Disease | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Intismeran | Phase 3 | Non-small Cell Lung Cancer | - | - |
Fluorouracil (5-FU) | Phase 3 | Urinary Bladder Neoplasms | - | - |
AzaSite | Phase 3 | Bacterial Conjunctivitis | - | - |
rosiglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Elbasvir/Grazoprevir Fixed Dose Combination | Phase 3 | Chronic HCV Infection | - | - |
VARIVAX™ New Seed Process | Phase 3 | Varicella | - | - |
Reformulated Raltegravir | Phase 3 | HIV Infection | - | - |
Pneumococcal Vaccine, Polyvalent (23-valent) | Phase 3 | Pneumococcal Infection | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Phase 3 | HPV Infections | - | - |
levoleucovorin | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
2XP HEPTAVAX™-II SC | Phase 3 | Hepatitis B | - | - |
V110 | Phase 3 | Pneumococcal Infection | - | - |
RotaTeq (V260) | Phase 3 | Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 | - | - |
Cetuximab plus Platinum-based Doublet Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Background PAH Therapy | Phase 3 | Pulmonary Arterial Hypertension | - | - |
MK-0524B | Phase 3 | Primary Hypercholesterolemia | - | - |
L-PZQ ODT 50 mg/kg | Phase 3 | Schistosomiasis | - | - |
boceprevir (SCH 503034) | Phase 3 | Chronic Hepatitis C | - | - |
lovastatin | Phase 3 | Atherosclerosis | - | - |
Aprepitant | Phase 3 | Post-operative Nausea | - | - |
DOR | Phase 3 | HIV-1 Infection | - | - |
MMRV (AMP) | Phase 3 | Measles | - | - |
Folinic Acid | Phase 3 | Metastatic Colorectal Cancer | - | - |
Lamivudine | Phase 3 | HIV Infections | - | - |
RotaTeq™ experimental formulation | Phase 3 | Rotavirus Gastroenteritis | - | - |
BIC/FTC/TAF | Phase 3 | HIV-1 Infection | - | - |
Ifinatamab Deruxtecan | Phase 3 | Castration-Resistant Prostatic Cancer | - | - |
denufosol tetrasodium (INS37217) Inhalation Solution | Phase 3 | Cystic Fibrosis | - | - |
Bomedemstat | Phase 3 | Thrombocythemia, Essential | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pembrolizumab (MK-3475) | Phase 3 | Merkel Cell Carcinoma | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
MK-0518 | Phase 3 | HIV Infections | - | - |
Grazoprevir 100mg / Elbasvir 50 mg FDC | Phase 3 | Chronic Hepatitis C Virus | - | - |
succinylcholine | Phase 3 | Neuromuscular Blockade | - | - |
Kuvan® | Phase 3 | Phenylketonuria | - | - |
Tulisokibart | Phase 3 | Hidradenitis Suppurativa | - | - |
MK-1084 | Phase 3 | Colon Adenocarcinoma | - | - |
Pioglitazone hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
BCG | Phase 3 | Urinary Bladder Neoplasms | - | - |
Rebif® | Phase 3 | Clinically Isolated Syndrome | - | - |
Zoster Vaccine, Live, (Oka-Merck) | Phase 3 | Varicella Virus Infection | - | - |
peg-IFN | Phase 3 | Hepatitis C, Chronic | - | - |
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets | Phase 3 | Chronic Hepatitis C | - | - |
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ | Phase 3 | Herpes Zoster | - | - |
Sitagliptin 100 mg/simvastatin 40 mg FDC | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Prevnar 13® | Phase 3 | Streptococcus Pneumoniae Infection | - | - |
MK0991, caspofungin acetate / Duration of Treatment: | Phase 3 | Fungal Infection | - | - |
Ertugliflozin 10 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
daptomycin | Phase 3 | Pneumonia, Bacterial | - | - |
MK0831 | Phase 3 | HIV Infections | - | - |
Frespaciguat | Phase 3 | Pulmonary Hypertension | - | - |
Preservative-Free Tafluprost | Phase 3 | Open-angle Glaucoma | - | - |
Palivizumab | Phase 3 | RSV Infection | - | - |
Ertugliflozin 5 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Rotateq™ | Phase 3 | Rotavirus Infections | - | - |
Clesrovimab | Phase 3 | Respiratory Syncytial Viruses | - | - |
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live) | Phase 3 | Measles | - | - |
alvimopan | Phase 3 | Ileus | - | - |
Filgrastim | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
V503 Vaccine | Phase 3 | Papillomavirus Infections | - | - |
granisetron | Phase 3 | Chemotherapy-induced Nausea and Vomiting (CINV) | - | - |
MK-8527 | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
PCV15 - Part B | Phase 3 | Pneumococcal Disease | - | - |
luspatercept | Phase 3 | B-Thalassemia | - | - |
Zilovertamab vedotin | Phase 3 | B-cell Acute Lymphoblastic Leukemia | - | - |
Saizen® A | Phase 3 | Children Born With Serious Intra-uterine Growth Retardation | - | - |
Doravirine, Tenofovir, Lamivudine | Phase 3 | HIV-1 Infection | - | - |
Pembrolizumab/Quavonlimab | Phase 3 | Colorectal Cancer | - | - |
MK-5172A | Phase 3 | Chronic Hepatitis C | - | - |
PegIntron (peginterferon alfa-2b; SCH 54031) | Phase 3 | Hepatitis | - | - |
Grazoprevir | Phase 3 | Chronic Hepatitis C (CHC) | - | - |
vinflunine | Phase 3 | Urothelial Cancer | - | - |
PEG-Intron | Phase 3 | Hepatitis C | - | - |
Granulocyte Colony-Stimulating Factor (G-CSF) | Phase 3 | DLBCL | - | - |
MK0217, alendronate sodium / Duration of Treatment: 1 Month | Phase 3 | Osteoporosis | - | - |
Nemtabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Emtricitabine/tenofovir disoproxil (FTC/TDF) | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
Zoster Vaccine, Live | Phase 3 | Herpes Zoster | - | - |
Efprezimod alfa | Phase 3 | Graft Versus Host Disease | - | - |
Zoster Vaccine, Live (AMP) | Phase 3 | Herpes Zoster | - | - |
Prevnar 13™ | Phase 3 | Pneumococcal Infections | - | - |
Cisplatin/Carboplatin | Phase 3 | Carcinoma, Squamous Cell of Head and Neck | - | - |
Pembrolizumab/Vibostolimab | Phase 3 | Lung Neoplasms | - | - |
Modified Process Hepatitis B Vaccine | Phase 3 | Hepatitis B | - | - |
ProQuad® manufactured with recombinant Human Albumin (rHA) | Phase 3 | Measles | - | - |
Gardasil™ | Phase 3 | Papillomavirus Infections | - | - |
Varicella Virus Vaccine Live (Oka-Merck) | Phase 3 | Varicella | - | - |
Fosaprepitant dimeglumine | Phase 3 | Chemotherapy-Induced Nausea and Vomiting (CINV) | - | - |
MK0557 | Phase 3 | Obesity | - | - |
V181 | Phase 3 | Healthy | - | - |
Aprepitant 125 mg | Phase 3 | Chemotherapy Induced Nausea and Vomiting | - | - |
Human Papillomavirus (HPV) 16 Monovalent | Phase 3 | Cervical Cancer | - | - |
PegIntron | Phase 3 | Hepatitis C | - | - |
Atropine | Phase 3 | Anesthesia, General | - | - |
Glycemic Rescue 1 | Phase 3 | Diabetes Mellitus | - | - |
Zoster Vaccine, Live (Zostavax™) | Phase 3 | Shingles | - | - |
DOR/ISL | Phase 3 | HIV Infection | - | - |
Rocuronium bromide (Org 9426) | Phase 3 | Muscle Relaxation | - | - |
Axitinib | Phase 3 | Renal Cell Carcinoma | - | - |
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pembrolizumab Formulated with Berahyaluronidase Alfa | Phase 3 | Metastatic Non-small Cell Lung Cancer | - | - |
Rocuronium 0.6 mg/kg intubating dose | Phase 3 | Anesthesia | - | - |
Androgen Deprivation Therapy (ADT) | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer | - | - |
Pneumovax™ 23 | Phase 3 | Pneumococcal Infections | - | - |
Glimerpiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
caspofungin acetate | Phase 3 | Fungal Infection | - | - |
Posaconazole | Phase 3 | Mycoses | - | - |
Metformin - Rescue | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Infanrix® hexa | Phase 3 | Varicella | - | - |
Cisplatin (as radiosensitizer) | Phase 3 | Endometrial Neoplasms | - | - |
Rocuronium bolus maintenance | Phase 3 | Anesthesia | - | - |
Vecuronium | Phase 3 | Anesthesia, General | - | - |
IV Tulisokibart | Phase 3 | Crohn's Disease | - | - |
Peginterferon alfa-2b (PEG2b) | Phase 3 | Hepatitis C, Chronic | - | - |
V114 | Phase 3 | Pneumococcal Infections | - | - |
Peg-interferon alfa-2b | Phase 3 | Hepatitis C, Chronic | - | - |
Daptomycin 4 mg/kg | Phase 3 | Staphylococcal Infection | - | - |
Gonalef® (Follitropin alfa) | Phase 3 | Infertility | - | - |
peg-Interferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Calderasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
ZOSTAVAX | Phase 3 | Herpes Zoster | - | - |
(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Phase 3 | Condylomata Acuminata | - | - |
Peginterferon | Phase 3 | Multiple Myeloma | - | - |
H2 Receptor Antagonist | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
RotaTeq® | Phase 3 | Meningitis, Meningococcal | - | - |
sitagliptin phosphate | Phase 3 | Type 2 Diabetes | - | - |
Infliximab | Phase 3 | Psoriasis | - | - |
Boceprevir (BOC) | Phase 3 | Chronic Hepatitis C | - | - |
Intismeran autogene | Phase 3 | Bladder Cancer | - | - |
MK0869, aprepitant | Phase 3 | Postoperative Nausea and Vomiting | - | - |
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks | Phase 3 | Foot Infections in Diabetic Patients | - | - |
Naproxen | Phase 3 | Endometriosis-related Pain | - | - |
Ertugliflozin 15 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pembrolizumab/Vibostolimab Co-Formulation | Phase 3 | Small Cell Lung Carcinoma | - | - |
Voriconazole | Phase 3 | Aspergillosis | - | - |
Short ragweed pollen allergen extract | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
MK0803, lovastatin | Phase 3 | Hypercholesterolemia | - | - |
fidaxomicin | Phase 3 | Clostridium Difficile-Associated Diarrhea (CDAD) | - | - |
MK-3475A | Phase 3 | Non-small Cell Lung Cancer | - | - |
Prevenar 13™ | Phase 3 | Pneumococcal Infections | - | - |
Trifluridine-Tipiracil | Phase 3 | Gastroesophageal Cancer | - | - |
Rescue medication | Phase 3 | Non-Muscle Invasive Bladder Cancer | - | - |
Tisotumab Vedotin | Phase 3 | Cervical Cancer | - | - |
Metformin IR | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pembrolizumab (K) | Phase 3 | Breast Cancer | - | - |
losartan potassium | Phase 3 | Hypertension | - | - |
niacin (+) laropiprant | Phase 3 | Hypercholesterolemia | - | - |
TAS-102 (trifluridine and tipiracil) | Phase 3 | Colorectal Neoplasms | - | - |
Diquafosol tetrasodium ophthalmic solution, 2% | Phase 3 | Dry Eye Disease | - | - |
favezelimab/pembrolizumab | Phase 3 | Hodgkin Lymphoma | - | - |
Golimumab | Phase 3 | Spondylitis, Ankylosing | - | - |
zoster vaccine live (ZOSTAVAX™) | Phase 3 | Herpes Zoster | - | - |
TAS-102 | Phase 3 | Colorectal Cancer | - | - |
Infliximab + methotrexate (MTX) | Phase 3 | Arthritis, Rheumatoid | - | - |
Montelukast | Phase 3 | Asthma | - | - |
anacetrapib | Phase 3 | Coronary Heart Disease (CHD) | - | - |
Zoster Vaccine Live | Phase 3 | Herpes Zoster | - | - |
Epirubicin | Phase 3 | Triple Negative Breast Neoplasms | - | - |
Enlicitide | Phase 3 | Hyperlipidemia | - | - |
Pergoveris® | Phase 3 | Infertility | - | - |
Meropenem | Phase 3 | Healthcare-Associated Pneumonia | - | - |
Suvorexant Low Dose (LD) | Phase 3 | Primary Insomnia | - | - |
ER niacin/laropiprant | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Gefapixant 15 mg BID | Phase 3 | Chronic Cough | - | - |
Standard of Care (SOC) | Phase 3 | Solid Tumors | - | - |
Enalapril | Phase 3 | Hypertension | - | - |
Tedizolid phosphate | Phase 3 | Acute Bacterial Skin and Skin Structure Infections | - | - |
r-hCG | Phase 3 | Infertility | - | - |
Ceftolozane/Tazobactam | Phase 3 | Complicated Intra-Abdominal Infection | - | - |
hMG | Phase 3 | Infertility | - | - |
Grazoprevir + Elbasvir | Phase 3 | Hepatitis C Infection | - | - |
dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - | - |
Cetuximab + concomitant boost radiotherapy | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
rofecoxib | Phase 3 | Prostate Cancer | - | - |
SC golimumab | Phase 3 | Arthritis, Rheumatoid | - | - |
ProQuad® | Phase 3 | Measles | - | - |
Sitagliptin 100 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Voglibose | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ER-niacin | Phase 3 | Primary Hypercholesterolaemia | - | - |
MK-1293 | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Bisoprolol/Amlodipine (Bisoprolol failed group) | Phase 3 | Hypertension | - | - |
PAR-101/OPT-80 | Phase 3 | Clostridium Infections | - | - |
ZOSTAVAX™ | Phase 3 | Herpes Zoster | - | - |
cetuximab + cisplatin + vinorelbine | Phase 3 | Non Small Cell Lung Cancer (NSCLC) | - | - |
RotaTeq™, rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - | - |
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) | Phase 3 | Papillomavirus Infections | - | - |
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
ER niacin (+) laropiprant (ERN/LRPT) | Phase 3 | Dyslipidemia | - | - |
Infliximab + methotrexate (IFX + MTX) | Phase 3 | Arthritis, Psoriatic | - | - |
MK0966; Rofecoxib / Duration of Treatment: 156 weeks | Phase 3 | Colorectal Adenoma | - | - |
Rebif New Formulation + prophylactic Ibuprofen | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Imipenem | Phase 3 | Bacterial Pneumonia | - | - |
Vorinostat | Phase 3 | Mesothelioma | - | - |
PPSV23 | Phase 3 | Pneumococcal Disease | - | - |
L50/H12.5/A5 | Phase 3 | Hypertension | - | - |
Boceprevir | Phase 3 | Chronic Hepatitis C Genotype 1 | - | - |
Esmirtazapine | Phase 3 | Insomnia | - | - |
MK0826, /Duration of Treatment : 8 Weeks | Phase 3 | Complicated Intra-Abdominal Infections | - | - |
PNEUMOVAX™23 | Phase 3 | Pneumococcal Infections | - | - |
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Phase 3 | Head and Neck Cancer | - | - |
Finasteride | Phase 3 | Enlarged Prostate | - | - |
raltegravir | Phase 3 | HIV | - | - |
MK0826, ertapenem sodium | Phase 3 | Infections | - | - |
sugammadex | Phase 3 | Neuromuscular Blockade | - | - |
hydrochlorothiazide (HCTZ) | Phase 3 | Hypertension | - | - |
pembrolizumab | Phase 3 | Colorectal Neoplasms | - | - |
Ertapenem sodium | Phase 3 | Infection; Diabetic Foot | - | - |
loratadine; montelukast | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
Recombinant Human Papillomavirus Nonavalent Vaccine | Phase 3 | AIDS-Related Human Papillomavirus Infection | - | - |
Pembrolizumab (+) Berahyaluronidase alfa | Phase 3 | Lung Cancer | - | - |
Tedizolid Phophate | Phase 3 | Skin Diseases, Infectious | - | - |
Isentress® | Phase 3 | HIV Infections | - | - |
MK0826, ertapenem sodium / Duration of Treatment: 14 Days | Phase 3 | Infection | - | - |
MK0507A, dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - | - |
Sitagliptin | Phase 3 | Hyperlipidemia | - | - |
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks | Phase 3 | Osteoporosis | - | - |
raltegravir potassium | Phase 3 | HIV Infections | - | - |
Vancomycin (or equivalent) | Phase 3 | Acute Hematogenous Osteomyelitis | - | - |
Insulin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | Phase 3 | Vomiting | - | - |
Calcium supplement | Phase 3 | Osteoporosis | - | - |
pneumococcal 23v polysaccharide vaccine | Phase 3 | Pneumococcal Infection | - | - |
niacin (+) laropiprant (+) simvastatin | Phase 3 | Primary Hypercholesterolemia | - | - |
Modified Process Hepatitis B Vaccine (Experimental) | Phase 3 | Hepatitis B | - | - |
rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - | - |
sitagliptin/metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Grazoprevir/Elbasvir | Phase 3 | Hepatitis C | - | - |
MK-6072 | Phase 3 | Clostridium Difficile Infection | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) | Phase 3 | Papillomavirus Infections | - | - |
V212 | Phase 3 | Herpes Zoster | - | - |
laropiprant/niacin (MK0524A) | Phase 3 | Hypercholesterolemia | - | - |
Riociguat (Adempas, BAY63-2521) | Phase 3 | Hypertension, Pulmonary | - | - |
9vHPV vaccine | Phase 3 | Papillomavirus Infections | - | - |
Gonal-f® | Phase 3 | Assisted Reproductive Techniques | - | - |
Dexamethasone 4 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
COL-1620 | Phase 3 | Luteal Hormone Supplementation in In-vitro Fertilization | - | - |
losartan potassium (+) hydrochlorothiazide | Phase 3 | Hypertension | - | - |
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine | Phase 3 | Diphtheria | - | - |
Open-label Metformin | Phase 3 | Type 2 Diabetes | - | - |
Acid Nicotinique | Phase 3 | Acute Coronary Syndrome (ACS) | - | - |
Interferon-alpha2b - 1 year | Phase 3 | Melanoma | - | - |
Pre-treatment with rLH (Luveris 75 IU), | Phase 3 | Infertility, Female | - | - |
Varicella-zoster vaccine | Phase 3 | Herpes Zoster | - | - |
V501 | Phase 3 | Human | - | - |
Preladenant | Phase 3 | Parkinson Disease | - | - |
Olaparib | Phase 3 | Ovarian Cancer | - | - |
Lantus™ | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Opevesostat | Phase 3 | Prostate Cancer Metastatic | - | - |
FTC/TDF + EFV or LPV/R +T20 | Phase 3 | HIV Infections | - | - |
Sotatercept | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
7-valent pneumococcal-CRM197 conjugate vaccine | Phase 3 | Otitis Media | - | - |
budesonide and montelukast | Phase 3 | Obstructive Sleep Apnea | - | - |
Avonex® | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Corifollitropin Alfa | Phase 3 | Infertility, Female | - | - |
Bezlotoxumab | Phase 3 | Clostridium Difficile Infection | - | - |
Metronidazole | Phase 3 | Complicated Intra-abdominal Infections | - | - |
Raptiva | Phase 3 | Moderate to Severe Psoriasis | - | - |
Pembrolizumab 400 mg | Phase 3 | Small Cell Lung Cancer | - | - |
mRNA-1273 Vaccine | Phase 3 | Papillomavirus Infections | - | - |
PCV20 | Phase 3 | Pneumococcal Infection | - | - |
Rescue Medications | Phase 3 | Cervical Cancer | - | - |
MTX | Phase 3 | Arthritis, Rheumatoid | - | - |
Elbasvir | Phase 3 | Hepatitis C | - | - |
Etoricoxib | Phase 3 | Knee Osteoarthritis | - | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Phase 3 | Cervical Cancer | - | - |
V920 Consistency Lot A | Phase 3 | Prevention of Ebola Infection | - | - |
raltegravir (Isentress) | Phase 3 | HIV Infections | - | - |
week 24 | Phase 3 | Peripheral Spondyloarthritis | - | - |
Peginterferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Phase 3 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | - | - |
Letermovir | Phase 3 | Cytomegalovirus Infection | - | - |
Ertugliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
0.9% sodium chloride (NaCl) | Phase 3 | Anesthesia | - | - |
Peginterferon alfa-2b | Phase 3 | Carcinoma, Hepatocellular | - | - |
V232 Modified Process Hepatitis B Vaccine: Lot A | Phase 3 | Hepatitis B Infection | - | - |
Ipragliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
PCV13 | Phase 3 | Pneumococcal Infections | - | - |
Rocuronium bromide | Phase 3 | Anesthesia | - | - |
IMI/REL | Phase 3 | Suspected or Documented Gram-negative Bacterial Infection | - | - |
INFANRIX™ hexa | Phase 3 | Bacterial Infections | - | - |
Letermovir 480 mg once daily | Phase 3 | Kidney Transplant; Complications | - | - |
PR5I | Phase 3 | Neisseria Meningitidis | - | - |
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) | Phase 3 | Varicella | - | - |
Anacetrapib 100 mg | Phase 3 | Hypercholesterolemia | - | - |
MK0966, rofecoxib | Phase 3 | Postoperative Pain | - | - |
Cladribine (MAVENCLAD®) | Phase 3 | Advanced Multiple Sclerosis | - | - |
Posaconazole oral suspension | Phase 3 | Mycoses | - | - |
Tobramycin | Phase 3 | Bacterial Conjunctivitis | - | - |
Delstrigo | Phase 3 | HIV-1-infection | - | - |
ezetimibe with simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Pegylated interferon alfa-2b | Phase 3 | Hepatitis C | - | - |
Follitropin alfa liquid formulation | Phase 3 | Infertility | - | - |
Gliclazide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Micronised Progesterone | Phase 3 | Infertility | - | - |
Imipenem+Cilastatin/Relebactam | Phase 3 | Complicated Intra-abdominal Infection | - | - |
MK-0524A | Phase 3 | Hypercholesteremia | - | - |
Basal Insulin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Ezetimibe + Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Supportive care measures | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Golimumab 50 mg SC | Phase 3 | Arthritis | - | - |
sac-TMT | Phase 3 | Non-small Cell Lung Cancer | - | - |
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A) | Phase 3 | Chronic Hepatitis C | - | - |
Org 50081 | Phase 3 | Insomnia | - | - |
ezetimibe (plus simvastatin) | Phase 3 | Atherosclerosis | - | - |
Doravirine | Phase 3 | HIV-1 | - | - |
Telcagepant | Phase 3 | Migraine | - | - |
Epacadostat | Phase 3 | Gastric Adenocarcinoma | - | - |
rolofylline | Phase 3 | Heart Failure, Congestive | - | - |
ZOSTAVAX™ (concomitant) | Phase 3 | Herpes Zoster | - | - |
HBVAXPRO™ | Phase 3 | Hepatitis B | - | - |
VARIVAX™ | Phase 3 | Varicella | - | - |
Lenvatinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
SC Tulisokibart | Phase 3 | Ulcerative Colitis | - | - |
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Phase 3 | Human Papillomavirus Infection | - | - |
Estrogens | Phase 3 | Infertility | - | - |
V116 | Phase 3 | Pneumococcal Infection | - | - |
Omarigliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Vericiguat | Phase 3 | Heart Failure | - | - |
MR Prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
DAPTACEL™ | Phase 3 | Bacterial Infections | - | - |
Pembrolizumab 200 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
Enpatoran | Phase 3 | Systemic Lupus Erythematosus (SLE) | - | - |
V260 | Phase 3 | Rotavirus Gastroenteritis | - | - |
IMI/REL FDC | Phase 3 | Hospital-Acquired Bacterial Pneumonia | - | - |
MK0974 50 mg | Phase 3 | Migraine | - | - |
sitagliptin 100 mg q.d./pioglitazone 30 mg q.d | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Combination of (a) pegylated interferon alfa-2b and (b) rebetol | Phase 3 | Liver Transplantation | - | - |
Gefapixant 45 mg twice daily (BID) | Phase 3 | Chronic Cough | - | - |
Patritumab Deruxtecan | Phase 3 | Malignant Neoplasm | - | - |
Epinephrine | Phase 3 | Malignant Neoplasms of Male Genital Organs | - | - |
Vicriviroc | Phase 3 | HIV Infections | - | - |
Simvastatin 20 mg daily | Phase 3 | Cardiovascular Disease | - | - |
alendronate with cholecalciferol | Phase 3 | Osteoporosis | - | - |
MK-8748 | Phase 3 | Diabetic Retinopathy | - | - |
Molnupiravir | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
Gefapixant | Phase 3 | Chronic Cough | - | - |
ertapenem sodium (MK0826) | Phase 3 | Urinary Tract Infection | - | - |
Pegylated liposomal doxorubicin (SCH 200746) | Phase 3 | Breast Cancer | - | - |
peginterferon alfa-2b (SCH 54031) | Phase 3 | Chronic Hepatitis C | - | - |
Pembrolizumab SC | Phase 3 | Non-Small Cell Lung Cancer | - | - |
MK0869, aprepitant / Duration of Treatment: 3 days | Phase 3 | Nausea | - | - |
ISL | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
TR-701 FA | Phase 3 | Skin and Subcutaneous Tissue Bacterial Infections | - | - |
Ridaforolimus | Phase 3 | Sarcoma | - | - |
V503 | Phase 3 | Papillomavirus Infections | - | - |
Gardasil | Phase 3 | Papillomavirus Infections | - | - |
Neostigmine | Phase 3 | Anesthesia | - | - |
5-Fluorouracil | Phase 3 | Uterine Cervical Neoplasms | - | - |
CB-183,315 | Phase 3 | Clostridium Difficile Infection | - | - |
Saizen® | Phase 3 | Fibromyalgia | - | - |
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live | Phase 3 | Measles | - | - |
ceftriaxone sodium | Phase 3 | Infection | - | - |
PCV15 | Phase 3 | Pneumonia, Pneumococcal | - | - |
mFOLFOX6 | Phase 3 | Colorectal Carcinoma | - | - |
eribulin | Phase 3 | Metastatic Triple Negative Breast Cancer | - | - |
Sitagliptin (MK0431) | Phase 3 | Diabetes Mellitus, Type II | - | - |
Sitagliptin 50 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Cisplatin 100 mg/m^2 | Phase 3 | Head and Neck Neoplasms | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Enlicitide Decanoate | Phase 3 | Hypercholesterolemia | - | - |
Odanacatib | Phase 3 | Osteoporosis Postmenopausal | - | - |
pegylated interferon alpha-2b | Phase 3 | Hepatitis B, Chronic | - | - |
neostigmine and glycopyrrolate or atropine | Phase 3 | Neuromuscular Blockade | - | - |
Preservative-Free Tafluprost or vehicle | Phase 3 | Glaucoma | - | - |
Preladenant 2 mg tablet | Phase 3 | Parkinson Disease | - | - |
V419 | Phase 3 | Bacterial Infections | - | - |
Suvorexant | Phase 3 | Insomnia | - | - |
Recombinant human luteinizing hormone (r-hLH) | Phase 3 | Hypogonadism | - | - |
Rocuronium | Phase 3 | Anesthesia, General | - | - |
Experimental: V503 | Phase 3 | Cervical Cancer | - | - |
vaniprevir | Phase 3 | Hepatitis C, Chronic | - | - |
Peginterferon alfa-2b (PegIntron, SCH 54031) | Phase 3 | Hepatitis D, Chronic | - | - |
RNF | Phase 3 | Multiple Sclerosis | - | - |
H1 receptor antagonist | Phase 3 | Ovarian Cancer | - | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years | Phase 3 | Cervical Cancer | - | - |
Telcagepant potassium 150 mg | Phase 3 | Migraine | - | - |
Cetrorelix acetate | Phase 3 | Polycystic Ovarian Syndrome | - | - |
Hepatitis A Vaccine, Purified Inactivated (VAQTA™) | Phase 3 | Hepatitis A Virus Infection | - | - |
Pegylated interferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
Sugammadex 0.5 mg/kg | Phase 3 | Anesthesia | - | - |
VARIVAX® PE34 Process | Phase 3 | Varicella | - | - |
INS365 Ophthalmic Solution | Phase 3 | Keratoconjunctivitis Sicca | - | - |
Rotavirus vaccine | Phase 3 | Bacterial Infections | - | - |
MK-8591A | Phase 3 | HIV-1 Infection | - | - |
Belzutifan | Phase 3 | Renal Cell Carcinoma | - | - |
Interferon-beta-1a | Phase 3 | Hepatitis C | - | - |
Dinaciclib | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Vorapaxar 2.5 mg | Phase 3 | Cerebral Infarction | - | - |
Rocurium | Phase 3 | Anesthesia, General | - | - |
Vericiguat tablet | Phase 3 | Heart Failure | - | - |
ATRIPLA™ | Phase 3 | Human Immunodeficiency Virus (HIV) | - | - |
MK-1045 | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Glipizide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Surotomycin | Phase 3 | Clostridium Difficile Infection | - | - |
Blinatumomab | Phase 3 | B-cell Acute Lymphoblastic Leukemia | - | - |
Anagrelide | Phase 3 | Essential Thrombocythemia | - | - |
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) | Phase 2 | Primary Biliary Cholangitis | - | - |
Arm A: Pemetrexed Cisplatin | Phase 2 | Non Small Cell Lung Cancer | - | - |
EVX-01 | Phase 2 | Melanoma Stage IV | - | - |
PembroRT | Phase 2 | Non-small Cell Lung Cancer, NSCLC | - | - |
Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) | Phase 2 | Recurrent Mantle Cell Lymphoma | - | - |
MK1903 | Phase 2 | Dyslipidemia | - | - |
MK-2206 | Phase 2 | PANCREAS | - | - |
Peginterferon alfa-2a (Peg-IFN) | Phase 2 | Hepatitis C, Chronic | - | - |
denufosol tetrasodium Inhalation Solution | Phase 2 | Cystic Fibrosis | - | - |
CXA-101 | Phase 2 | Complicated Urinary Tract Infection | - | - |
MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks | Phase 2 | Hypercholesterolemia | - | - |
pegylated interferon | Phase 2 | Chronic Hepatitis C | - | - |
Multiple low dose cyclophosphamide | Phase 2 | Multiple Myeloma | - | - |
Azacitadine | Phase 2 | Acute Myeloid Leukemia | - | - |
Cisplatin (TP) | Phase 2 | Squamous Cell Carcinoma of the Hypopharynx | - | - |
pIL-12 | Phase 2 | Melanoma | - | - |
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER | Phase 2 | Solid Tumor, Adult | - | - |
LY3537982 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Butantan - DV | Phase 2 | Dengue | - | - |
denufosol tetrasodium (INS37217) | Phase 2 | Cystic Fibrosis | - | - |
OPT-80 | Phase 2 | Diarrhea | - | - |
Dalotuzumab | Phase 2 | Carcinoma, Non-small-cell Lung | - | - |
MK-8777 | Phase 2 | Depression | - | - |
ARQ 197 | Phase 2 | Pancreatic Neoplasms | - | - |
ARQ 501 | Phase 2 | Cancer | - | - |
Robatumumab | Phase 2 | Colorectal Cancer | - | - |
ADL5945 0.1 mg | Phase 2 | Opioid Induced Constipation | - | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks | Phase 2 | Diabetes Mellitus, Type II | - | - |
M5717 330 mg | Phase 2 | Acute Malaria | - | - |
Vibostolimab | Phase 2 | Melanoma | - | - |
MK0493 | Phase 2 | Obesity | - | - |
MK0812 / Duration of Treatment: 12 Weeks | Phase 2 | Arthritis, Rheumatoid | - | - |
INS37217 Nasal Spray | Phase 2 | Perennial Allergic Rhinitis | - | - |
MK0777 | Phase 2 | Generalized Anxiety Disorder | - | - |
Uprifosbuvir | Phase 2 | Hepatitis C | - | - |
Pneumococcal Conjugate Vaccine (V114) | Phase 2 | Pneumococcal Infections | - | - |
V114 Aluminum-adjuvanted | Phase 2 | Pneumococcal Infections | - | - |
Vibostolimab/Pembrolizumab | Phase 2 | Carcinoma, Renal Cell | - | - |
MK-3120 | Phase 2 | Urothelial Carcinoma | - | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Navarixin | Phase 2 | Solid Tumors | - | - |
Daptomycin for Injection | Phase 2 | Bacteremia | - | - |
UFOX + Cetuximab | Phase 2 | Previously Untreated Metastatic Colorectal Cancer | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Raludotatug Deruxtecan (R-DXd) | Phase 2 | Gastrointestinal Cancer | - | - |
Tepotinib | Phase 2 | Non-small Cell Lung Cancer | - | - |
MK-3795 | Phase 2 | VHL Gene Mutation | - | - |
V114 Lot 1 | Phase 2 | Pneumococcal Infections | - | - |
adavosertib | Phase 2 | Ovarian Cancer | - | - |
MK0249 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - | - |
MK-8435 (Org 25935) 4-8 mg | Phase 2 | Schizophrenia | - | - |
MK-6096 | Phase 2 | Migraine | - | - |
Pembrolizumab/vibostolimab coformulation | Phase 2 | Bladder Cancer | - | - |
irinotecan hydrochloride | Phase 2 | Metastatic Colorectal Cancer | - | - |
MK-0941 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Vaniprevir 600 mg b.i.d. | Phase 2 | Hepatitis C, Chronic | - | - |
IDX719 | Phase 2 | Hepatitis C, Chronic | - | - |
MK2295 | Phase 2 | Pain, Postoperative | - | - |
Quavonlimab | Phase 2 | Advanced Solid Tumors | - | - |
MK-1167 | Phase 2 | Alzheimer Disease | - | - |
SCH 530348 | Phase 2 | Arterial Obstructive Diseases | - | - |
Epinastine Nasal Spray | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Merck L-830982 | Phase 2 | Schizophrenia | - | - |
Avelumab | Phase 2 | Squamous Non-Small Cell Lung Cancer | - | - |
MK-4830 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
zoster vaccine live (Oka/Merck) | Phase 2 | Shingles | - | - |
Raludotatug Deruxtecan | Phase 2 | Ovarian Cancer Recurrent | - | - |
Coformulation favezelimab/pembrolizumab | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Fosaprepitant | Phase 2 | Chemotherapy-induced Nausea and Vomiting | - | - |
Gefapixant 45 mg | Phase 2 | Chronic Cough | - | - |
Farnesyl Protein Transferase Inhibitor | Phase 2 | Leukemia | - | - |
ADL5859 | Phase 2 | Peripheral Neuropathy | - | - |
MK2461 | Phase 2 | Neoplasm | - | - |
MK0991, caspofungin acetate | Phase 2 | Aspergillosis | - | - |
SCH 486757 | Phase 2 | Cough | - | - |
Tecemotide (L-BLP25) | Phase 2 | Lung Neoplasms | - | - |
measles, mumps, and rubella virus vaccine live | Phase 2 | Measles | - | - |
AS900672-Enriched 50 microgram (mcg) | Phase 2 | Infertility | - | - |
Cilengitide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
ecallantide | Phase 2 | Bloodloss | - | - |
Pembrolizumab (neoadjuvant) | Phase 2 | Lung Neoplasm Malignant | - | - |
MK0518 | Phase 2 | HIV Infections | - | - |
ADL5945 0.25 mg | Phase 2 | Constipation | - | - |
ENB003 | Phase 2 | Cancer | - | - |
MK-5684 | Phase 2 | Malignant Neoplasm | - | - |
Attenuvax | Phase 2 | HIV Infections | - | - |
TU2218 + KEYTRUDA® (Pembrolizumab) | Phase 2 | Solid Tumor | - | - |
Ertugliflozin 1 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
M5049 low dose | Phase 2 | Systemic Lupus Erythematosus | - | - |
Pegylated Interferon Alfa | Phase 2 | Chronic Hepatitis C | - | - |
KW-3902IV | Phase 2 | Heart Failure, Congestive | - | - |
Favezelimab | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
tildrakizumab | Phase 2 | Psoriasis | - | - |
SCH 900538 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
EBR/GZR FDC Tablet | Phase 2 | HCV Infection | - | - |
MK0916 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
V160 | Phase 2 | Cytomegalovirus (CMV) Infections | - | - |
MK-2140 (zilovertamab vedotin) | Phase 2 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | - | - |
Cabazitaxel | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - | - |
L-dopa | Phase 2 | Parkinson Disease | - | - |
MK0364 | Phase 2 | Obesity | - | - |
Single low dose cyclophosphamide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
MK-8189 | Phase 2 | Schizophrenia, Acute Episode | - | - |
Recombinant human growth hormone (r-hGH) | Phase 2 | Hypochondroplasia | - | - |
CyPep-1 | Phase 2 | Advanced Head and Neck Squamous Cell Carcinoma | - | - |
Stavudine | Phase 2 | HIV Infections | - | - |
Pembrolizumab and Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
Boserolimab | Phase 2 | Small Cell Lung Cancer | - | - |
2 NRTIs | Phase 2 | Human Immunodeficiency Virus (HIV) Infection | - | - |
PegIFN-2b | Phase 2 | HIV Infections | - | - |
PegIntron (peginterferon alfa-2b) | Phase 2 | Hepatitis C, Chronic | - | - |
Relebactam 250 mg | Phase 2 | Intra-abdominal Infections | - | - |
Atorvastatin/niacin extended-release | Phase 2 | Carotid Atherosclerosis | - | - |
Rebif | Phase 2 | Multiple Sclerosis | - | - |
MK-0873 | Phase 2 | Rheumatoid Arthritis | - | - |
Matuzumab | Phase 2 | Esophageal Cancer | - | - |
V504 | Phase 2 | Cervical Cancer | - | - |
imipenem/cilastatin 500 mg | Phase 2 | Urinary Tract Infections | - | - |
cetuximab, cisplatin | Phase 2 | Breast Neoplasm | - | - |
Interferon beta-1a | Phase 2 | Alzheimer's Disease | - | - |
V114 Medium Dose | Phase 2 | Pneumococcal Infections | - | - |
V181 High-Potency Level | Phase 2 | Dengue Disease | - | - |
cyclophosphamide (CPA) | Phase 2 | Rectal Cancer | - | - |
Biltricide (racemate praziquantel) oral tablets | Phase 2 | Schistosomiasis | - | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - | - |
SCH 900636 | Phase 2 | Depressive Disorders | - | - |
Pegylated Lyposomal Doxorubicin | Phase 2 | Breast Neoplasm | - | - |
MK0782 | Phase 2 | Stomach Ulcer | - | - |
EMD 525797 250 mg | Phase 2 | Metastatic Colorectal Cancer | - | - |
TR701 FA | Phase 2 | Major Cutaneous Abscess | - | - |
Doravirine, Tenofovir, Lamivudine - Blinded | Phase 2 | HIV-1 | - | - |
V940 | Phase 2 | Squamous Non-small Cell Lung Cancer | - | - |
R-DXD | Phase 2 | Lung Neoplasm | - | - |
Efinopegdutide | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - | - |
PRA023 IV | Phase 2 | Crohn Disease | - | - |
Zolinza (vorinostat) | Phase 2 | Lymphoma | - | - |
Metolazone | Phase 2 | Heart Failure | - | - |
Suvorexant 20 mg | Phase 2 | Delirium in Old Age | - | - |
ST-067 | Phase 2 | Cancer | - | - |
Miransertib | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | - | - |
MK-0893 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ZA | Phase 2 | Breast Cancer | - | - |
L-756423 | Phase 2 | HIV Infections | - | - |
timolol/dorzolamide combination | Phase 2 | Glaucoma | - | - |
AO-176 | Phase 2 | Solid Tumor | - | - |
Esmeron® | Phase 2 | Neuromuscular Blockade | - | - |
NM283 plus Peg-IFNα-2a | Phase 2 | Chronic Hepatitis C | - | - |
Gefapixant 50 mg | Phase 2 | Asthma | - | - |
MK-2060 | Phase 2 | End-Stage Renal Disease | - | - |
IDX184 | Phase 2 | Chronic Hepatitis C Infection | - | - |
Pleconaril | Phase 2 | Asthma | - | - |
KVA12123 - Dose Escalation | Phase 2 | Cancer | - | - |
Gocatamig | Phase 2 | Small-Cell Lung Cancer | - | - |
MK-1200 | Phase 2 | Advanced Solid Tumors | - | - |
SCH 727965 | Phase 2 | Breast Neoplasms | - | - |
V114-A | Phase 2 | Pneumococcal Infections | - | - |
IFN beta 1a 44 mcg TIW | Phase 2 | Multiple Sclerosis | - | - |
Pegylated Liposomal Doxorubicin | Phase 2 | Breast Neoplasm | - | - |
Tepotinib 300 mg | Phase 2 | Carcinoma, Hepatocellular | - | - |
Lenvatinib Capsules | Phase 2 | Hepatocellular Carcinoma | - | - |
Avastin | Phase 2 | High-grade Serous Ovarian Carcinoma | - | - |
Atacicept | Phase 2 | Rheumatoid Arthritis | - | - |
Vibegron | Phase 2 | Urinary Bladder, Overactive | - | - |
Org 34517 | Phase 2 | Depression | - | - |
MK-1029 | Phase 2 | Asthma | - | - |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | Phase 2 | HIV-1 Infection | - | - |
CRS-207 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Lenvatinib Oral Product | Phase 2 | Merkel Cell Carcinoma | - | - |
Coformulated favezelimab/pembrolizumab | Phase 2 | Metastatic Urothelial Carcinoma | - | - |
val-mCyd | Phase 2 | Chronic Hepatitis C | - | - |
Gefapixant 100 mg | Phase 2 | Refractory Chronic Cough | - | - |
Radium-223 | Phase 2 | Prostate Cancer | - | - |
Vicriviroc 30 mg | Phase 2 | HIV Infections | - | - |
valopicitabine | Phase 2 | Chronic Hepatitis C | - | - |
MK0677 | Phase 2 | Alzheimer's Disease | - | - |
Interferon-beta-1a, 44 microgram | Phase 2 | Ulcerative Colitis | - | - |
MK0991, caspofungin acetate/Duration of Treatment: variable | Phase 2 | Candidiasis | - | - |
TRUVADA® | Phase 2 | HIV Infections | - | - |
Antihistamine | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
Oral testosterone undecanoate (Andriol) | Phase 2 | Hypogonadism | - | - |
Dalantercept | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Sugar Pill | Phase 2 | Osteoarthritis of the Knee | - | - |
Sotatercept 0.3 mg/kg | Phase 2 | Hypertension, Pulmonary | - | - |
Vorapaxar | Phase 2 | Atherosclerosis | - | - |
Docetetaxel | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Pertuzumab | Phase 2 | Breast Neoplasms | - | - |
epinastine 0.1% | Phase 2 | Allergic Rhinitis | - | - |
MK-8998 | Phase 2 | Schizophrenia | - | - |
ATX-MS-1467 | Phase 2 | Multiple Sclerosis | - | - |
Dalantercept plus sorafenib | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - | - |
AR51 (12, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - | - |
EV | Phase 2 | Bladder Cancer | - | - |
MK0974 | Phase 2 | Migraine | - | - |
diphenhydramine | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
MK-8616 | Phase 2 | Neuromuscular Blockade | - | - |
Pembrolizumab 25 MG/ML [KEYTRUDA®] | Phase 2 | Advanced Solid Tumor Malignancy | - | - |
Benznidazole | Phase 2 | Chagas Disease | - | - |
FF-10832 | Phase 2 | Advanced Urothelial Carcinoma | - | - |
raltegravir and etravirine | Phase 2 | HIV-1 Infection | - | - |
Ertugliflozin 25 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
MK8141 | Phase 2 | Hypertension | - | - |
MK0822A | Phase 2 | Vitamin D Deficiency | - | - |
MK0633 | Phase 2 | Atherosclerosis | - | - |
MK633 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Doxorubicin hydrochloride | Phase 2 | Breast Neoplasms | - | - |
r-FSH | Phase 2 | Ovarian Stimulation | - | - |
Enclitide Chloride | Phase 2 | Hypercholesterolemia | - | - |
Pimicotinib | Phase 2 | Tenosynovial Giant Cell Tumor | - | - |
coformulation pembrolizumab/quavonlimab | Phase 2 | Small Cell Lung Carcinoma | - | - |
ATRA | Phase 2 | Melanoma | - | - |
MK-2214 | Phase 2 | Early Alzheimer's Disease | - | - |
Dabrafenib | Phase 2 | Melanoma | - | - |
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks | Phase 2 | Flushing | - | - |
ridaforolimus (MK8669) | Phase 2 | Prostate Cancer | - | - |
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Phase 2 | B-cell Lymphoma | - | - |
Rolapitant Dose 1 | Phase 2 | Postoperative Nausea and Vomiting | - | - |
MK0359 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
MK0524 | Phase 2 | Seasonal Allergies | - | - |
peginterferon alfa 2b | Phase 2 | Hepatitis C, Chronic | - | - |
TS-1 | Phase 2 | Gastric Cancer | - | - |
Rescue | Phase 2 | Type II Diabetes Mellitus | - | - |
Tivantinib | Phase 2 | Advanced Solid Tumors | - | - |
Recombinant human follicle stimulating hormone (r-hFSH) | Phase 2 | Infertility | - | - |
Itraconazole | Phase 2 | Chronic Hepatitis C | - | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501) | Phase 2 | HPV Infections | - | - |
Pegylated Interferon (peg-IFN) | Phase 2 | Hepatitis C | - | - |
Ifinatamab Deruxtecan (I-DXd) | Phase 2 | Small Cell Lung Cancer | - | - |
Ruzasvir | Phase 2 | Hepatitis C | - | - |
Letermovir oral granules | Phase 2 | Cytomegalovirus (CMV) Infection | - | - |
Raltegravir Film-coated Tablet | Phase 2 | HIV Infection | - | - |
teicoplanin | Phase 2 | Osteomyelitis | - | - |
SCH 900271 15mg | Phase 2 | Primary Hypercholesterolemia | - | - |
MK5757 | Phase 2 | Schizophrenia | - | - |
Samatasvir | Phase 2 | Chronic Hepatitis C Virus | - | - |
Ulevostinag | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
ARQ 501 in combination with gemcitabine | Phase 2 | Pancreatic Cancer | - | - |
V205C, measles, mumps, and rubella virus vaccine live | Phase 2 | Measles | - | - |
medroxyprogesterone acetate tablets OR megestrol acetate | Phase 2 | Endometrial Cancer | - | - |
Posaconazole IV 6 mg/kg | Phase 2 | Invasive Fungal Infection | - | - |
Islatravir | Phase 2 | HIV-1 Infection | - | - |
RSV A Memphis 37b | Phase 2 | Respiratory Syncytial Virus | - | - |
SCH 619734 | Phase 2 | Cough | - | - |
ADL5747 | Phase 2 | Osteoarthritis of the Knee | - | - |
TR-701 200 mg | Phase 2 | Skin Diseases, Infectious | - | - |
Efinopegdutide 20 mg/mL | Phase 2 | Nonalcoholic Fatty Liver Disease | - | - |
Sitagliptin 25 mg | Phase 2 | Glucose Intolerance | - | - |
ADL5859 30 mg | Phase 2 | Acute Pain | - | - |
MK3207- 2.5 mg | Phase 2 | Migraine | - | - |
Grazoprevir (GZR) | Phase 2 | Hepatitis C Virus | - | - |
I-DXd | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
SCH 56592 | Phase 2 | Onychomycosis | - | - |
MK0524A, /Duration of Treatment : 8 Weeks | Phase 2 | Flushing | - | - |
Grazoprevir/Elbasvir FDC | Phase 2 | Hepatitis C | - | - |
MK-5442 | Phase 2 | Osteoporosis | - | - |
Caspofungin | Phase 2 | Candidiasis, Esophageal | - | - |
M5717 60 mg | Phase 2 | Malaria Infection | - | - |
SCH 497079 | Phase 2 | Obesity | - | - |
tretinoin | Phase 2 | Acute Myeloid Leukemia | - | - |
MK0826, ertapenem sodium /Duration of Treatment: 14 Days | Phase 2 | Urinary Tract Infections | - | - |
MK-0482 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
MK0736 | Phase 2 | Hypertension | - | - |
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20 | Phase 2 | Papillomavirus Infections | - | - |
MK0686 | Phase 2 | Pain, Postoperative | - | - |
MK-6213 | Phase 2 | Hypercholesterolemia | - | - |
VigantOL oil plus interferon beta-1a (Rebif) | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
Vicriviroc maleate | Phase 2 | HIV | - | - |
MK-8690 | Phase 2 | Colitis Ulcerative | - | - |
Olaparib 400 mg | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
MK0429 | Phase 2 | Post-Menopausal Osteoporosis | - | - |
Letermovir Pill | Phase 2 | CMV | - | - |
Ensifentrine | Phase 2 | COPD | - | - |
MK-0634 50 mg | Phase 2 | Urinary Incontinence | - | - |
ridaforolimus + dalotuzumab | Phase 2 | Breast Cancer | - | - |
rolofyline | Phase 2 | Congestive Heart Failure | - | - |
Posaconazole IV | Phase 2 | Invasive Aspergillosis | - | - |
MK-1029 150 mg | Phase 2 | Asthma | - | - |
r-hFSH | Phase 2 | Infertility | - | - |
Cilengitide 2000 mg once weekly | Phase 2 | Squamous Cell Cancer | - | - |
Navarixin 10 mg | Phase 2 | Psoriasis | - | - |
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks | Phase 2 | HIV Infections | - | - |
PR51 (3, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - | - |
carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles | Phase 2 | Squamous Cell Carcinoma of Larynx | - | - |
Methotrexate 1 GM Injection | Phase 2 | Gestational Trophoblastic Neoplasias (GTN) | - | - |
TEW-7197 | Phase 2 | Metastatic Colorectal Cancer | - | - |
M9140 | Phase 2 | Solid Tumors | - | - |
Imprime PGG | Phase 2 | Malignant Neoplasm of Breast | - | - |
Crinone 8% | Phase 2 | Postmenopausal Endometrium | - | - |
Mirdametinib | Phase 2 | Central Nervous System Tumors | - | - |
Bintrafusp Alfa | Phase 2 | Nasopharyngeal Carcinoma | - | - |
Pembrolizumab (Keytruda) | Phase 2 | Thyroid Cancer | - | - |
Axatilimab | Phase 2 | TNBC - Triple-Negative Breast Cancer | - | - |
Alendronate | Phase 2 | Osteoporosis | - | - |
Nirogacestat | Phase 2 | Tumor | - | - |
Boceprevir, Peg-interferon alfa 2b and Ribavirin | Phase 2 | HCV Coinfection | - | - |
Peg-Interferon α-2b or Peg-Interferon α-2a | Phase 2 | HCV Infection | - | - |
Pembrolizumab Injection [Keytruda] | Phase 2 | Malignant Neoplasm of Breast | - | - |
ATG-022 | Phase 2 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | - | - |
ART Intensification | Phase 2 | HIV-1 Infection | - | - |
Allogeneic cytomegalovirus-specific T cells | Phase 2 | Glioblastoma Multiforme | - | - |
ADV/HSV-tk | Phase 2 | Metastatic Non-small Cell Lung Cancer | - | - |
Testosterone Enanthate | Phase 2 | Male Hypogonadism | - | - |
BET Bromodomain Inhibitor ZEN-3694 | Phase 2 | Castration-Resistant Prostate Carcinoma | - | - |
olaparibp, embro | Phase 2 | Ovarian Cancer | - | - |
aprepitant, ondansetron, dexamethasone | Phase 2 | Nausea | - | - |
azacytidine | Phase 2 | Lymphoma | - | - |
galinpepimut-S | Phase 2 | Acute Myelogenous Leukemia | - | - |
Neoadjuvant Pembrolizumab | Phase 2 | Breast Cancer | - | - |
Entereg | Phase 2 | Laparoscopic Colonic Resection | - | - |
D-1553 | Phase 2 | Solid Tumor, Adult | - | - |
Bilastine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Q901 | Phase 2 | Advanced Cancer | - | - |
5HT3 | Phase 2 | Chemotherapy-Induced Nausea and Vomiting | - | - |
FOLFIRI + Cetuximab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Prednisone 5Mg | Phase 2 | Prostate Cancer Aggressiveness | - | - |
GVAX Pancreatic Cancer Vaccine | Phase 2 | Pancreatic Cancer | - | - |
Lenvatinib Mesylate | Phase 2 | Kidney Cancer | - | - |
Polatuzumab vedotin | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
IMGN853 | Phase 2 | Endometrial Cancer | - | - |
GAd-209-FSP low dose | Phase 2 | Solid Tumor, Adult | - | - |
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate | Phase 2 | Metastatic Malignant Neoplasm in the Liver | - | - |
Vinblastine | Phase 2 | Classical Hodgkin Lymphoma | - | - |
Defactinib | Phase 2 | Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
ACE-536 | Phase 2 | Beta-Thalassemia | - | - |
Paclitaxel 45 mg/m^2 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Pembrolizuma | Phase 2 | Metastatic Breast Cancer | - | - |
Vorinostat Velcade Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Pembrolizumab with All-Trans Retinoic Acid | Phase 2 | Stage IV Melanoma | - | - |
Elpipodect | Phase 2 | Schizophrenia | - | - |
CXA-101/ tazobactam and metronidazole | Phase 2 | Complicated Intra-abdominal Infection | - | - |
ABL103 | Phase 2 | Solid Tumors | - | - |
pembrolizumab, gemcitabine and cisplatin | Phase 2 | Bladder Cancer | - | - |
Ezetimibe/Simvastatin | Phase 2 | Type 1 Diabetes Mellitus | - | - |
R-CHOP Protocol | Phase 2 | B Cell Lymphoma | - | - |
MK-3475 (neoadjuvant) | Phase 2 | Cancer of Head and Neck | - | - |
Bemcentinib | Phase 2 | Lung Cancer Metastatic | - | - |
Pembrolizumab 200 mg IV infusion | Phase 2 | Stage IIIB(N2) Non-small Cell Lung Cancer | - | - |
Poly-ICLC | Phase 2 | Metastatic Colon Cancer | - | - |
Pegylated Interferon alpha 2b | Phase 2 | HIV-1 Infection | - | - |
UFT | Phase 2 | Metastatic Colorectal Cancer | - | - |
Vinblastine Sulfate | Phase 2 | Stage II Bladder Cancer AJCC v8 | - | - |
DPX-Survivac | Phase 2 | Relapsed Diffuse Large B-cell Lymphoma | - | - |
Bacillus Calmette-Guérin (BCG) | Phase 2 | Bladder Cancer | - | - |
HIF-2alpha Inhibitor PT2385 | Phase 2 | Recurrent Glioblastoma | - | - |
pTVG-HP | Phase 2 | Castration-resistant Prostate Cancer | - | - |
emtricitabine / tenofovir disoproxil fumarate / raltegravir . | Phase 2 | HIV-2 Infection | - | - |
GSK2636771 | Phase 2 | Melanoma and Other Malignant Neoplasms of Skin | - | - |
Human Papillomavirus vaccine | Phase 2 | Cervical High Grade Squamous Intraepithelial Lesion | - | - |
Tinodasertib | Phase 2 | Metastatic Colorectal Cancer | - | - |
Azithromycin ophthalmic solution, 1% | Phase 2 | Blepharitis | - | - |
Aprepitant/Ramosetron/Dexamethasone | Phase 2 | Chemotherapy-Induced Nausea and Vomiting | - | - |
Zepatier | Phase 2 | End Stage Renal Disease | - | - |
Prednisone or prednisolone | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Sitagliptin + Metformin | Phase 2 | Pre-diabetes | - | - |
ACP-196 in combination with pembrolizumab | Phase 2 | Metastatic Urothelial Carcinoma | - | - |
Letermovir 480 MG [Prevymis] | Phase 2 | Cytomegalovirus Infections | - | - |
Cefepime | Phase 2 | Other Infectious Diseases | - | - |
Pegzilarginase | Phase 2 | Small-cell Lung Cancer | - | - |
Spevatamig (PT886) | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma | - | - |
Pembrolizumab 25 MG/1 ML Intravenous Solution | Phase 2 | Metastatic Uveal Melanoma | - | - |
MK-1775 and carboplatin | Phase 2 | Epithelial Ovarian Cancer | - | - |
EIDD-2801 | Phase 2 | SARS-CoV 2 | - | - |
Gemox, Cetuximab | Phase 2 | Advanced Biliary Cancer | - | - |
Encorafenib Oral Capsule + Cetuximab | Phase 2 | Colorectal Cancer | - | - |
cetuximab, cisplatin, capecitabine | Phase 2 | Gastric Cancer | - | - |
Epclusa | Phase 2 | Lung Diseases | - | - |
acetominophen | Phase 2 | Migraine | - | - |
FLOT | Phase 2 | Esophagogastric Adenocarcinoma | - | - |
Afatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Hyperpolarized 13C-Pyruvate | Phase 2 | Neuroendocrine Tumors | - | - |
Cyklokapron(R) | Phase 2 | Bloodloss | - | - |
IMG-7289 | Phase 2 | Thrombocythemia, Essential | - | - |
cis/carboplatin and etoposide | Phase 2 | Small Cell Lung Cancer (SCLC) | - | - |
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) | Phase 2 | Ebola Virus Disease | - | - |
Molnupiravir 200 mg | Phase 2 | SARS-CoV-2 Infection, COVID-19 | - | - |
MK-0646 | Phase 2 | Neuroendocrine Tumors | - | - |
Ibutamoren Mesylate (MK-0677) | Phase 2 | Fibromyalgia | - | - |
Pembrolizumab, Cetuximab | Phase 2 | HNSCC | - | - |
TILT-123 | Phase 2 | Platinum-refractory Ovarian Carcinoma | - | - |
Capecitabine/ 5-FU | Phase 2 | Colorectal Cancer | - | - |
Cetuximab (Erbitux) | Phase 2 | Cancer | - | - |
FOLFOX-4+cetuximab | Phase 2 | Colorectal Cancer | - | - |
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) | Phase 2 | Cancer Survivor | - | - |
Nesuparib | Phase 2 | Endometrial Cancer | - | - |
Odetiglucan | Phase 2 | Colorectal Adenocarcinoma Metastatic in the Liver | - | - |
rVSVΔG-ZEBOV-GP, V920 | Phase 2 | Ebola Virus Disease | - | - |
Ataluren + Pembrolizumab | Phase 2 | Colorectal Cancer | - | - |
Cyclophosphamide 50mg | Phase 2 | Metastatic Breast Cancer | - | - |
Lonafarnib | Phase 2 | Breast Cancer | - | - |
breast cancer
2 drugs in this indication
cancer
2 drugs in this indication
HPV vaccine
1 drug in this indication
muscle invasive bladder cancer
1 drug in this indication
Muscle-invasive bladder cancer (MIBC), neoadjuvant and adjuvant treatment
1 drug in this indication
Non Small Cell Lung Cancer
1 drug in this indication
Melanoma Stage IV
1 drug in this indication
dMMR endometrial cancer
1 drug in this indication
Ebola
1 drug in this indication
oncology
1 drug in this indication
first-line treatment (specific indication not stated)
1 drug in this indication
cholesterol
1 drug in this indication
to reduce LDL-C in adults with hypercholesterolemia
1 drug in this indication
dMMR advanced or recurrent endometrial cancer
1 drug in this indication
cardiovascular disease
1 drug in this indication
Hypercholesterolemia (high levels of bad cholesterol)
1 drug in this indication
resectable muscle-invasive bladder cancer (MIBC)
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Dyslipidemia
1 drug in this indication
cholesterol-lowering
1 drug in this indication
PCSK9 inhibitor for LDL-C and Lp(a) lowering
1 drug in this indication
Hepatitis C
1 drug in this indication
PANCREAS
1 drug in this indication
HIV PrEP
1 drug in this indication
Melanoma
1 drug in this indication
Recurrent Mantle Cell Lymphoma
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
kidney cancer
1 drug in this indication
Diabetic Macular Edema (DME)
1 drug in this indication
advanced renal cell carcinoma
1 drug in this indication
diabetic macular edema
1 drug in this indication
eye disease
1 drug in this indication
Non-small Cell Lung Cancer, NSCLC
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MERCK's drug pipeline?→
CatalystAlert tracks 837 drug candidates in MERCK's (MRK) pipeline across Phase 3, Phase 2. Its lead program is ULO (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MERCK's next FDA catalyst?→
MERCK's (MRK) next tracked catalyst is a Phase 3 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRK biotech catalysts?→
Add MRK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MERCK's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
